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ABSTRACT
BACKGROUND
Lower abdominal surgeries like hernioplasty, abdominal hysterectomy are
commonly performed surgeries. Providing good analgesia with adequate muscle
relaxation during intra operative period and managing pain in the post operative
period is a good practice of anaesthesia. As pain influences the morbidity and
mortality of the patients, it’s important to ease pain due to surgery for better outcome
of the patients.
Commonly, lower abdominal surgeries are performed under spinal anaesthesia,
as it is easy to perform, single shot technique when compared to epidural anaesthesia
and general anaesthesia. But the main problem of spinal anaesthesia is that
postoperative analgesia lasts only for considerable period.
This study is conducted to analyse the effect of adding additives 50 µ of
neostigmine and 50 µ of clonidine to 0.5% hyperbaric bupivacaine and evaluating the
duration of postoperative analgesia with each drug and the intraoperative
haemodynamic stability in patients undergoing lower abdominal surgeries.
AIM:
To study the better adjuvant for intrathecal bupivacaine to achieve better
quality regional block with stable haemodynamic status and good postoperative pain
relief.
OBJECTIVES:
The objective of the study is comparative evaluation of clonidine and
neostigmine with 0.5% hyperbaric bupivacaine in spinal anaesthesia with respect to
Onset time for sensory block
Onset time for motor block
Level of sensory blockade
Quality of motor blockade
Intraoperative haemodynamics
Duration of postoperative analgesia
Quality of postoperative analgesia and Adverse effects
MATERIALS AND METHODS
Study involves adult patients aged between 18 – 60 years, ASA grade 1 and 2
posted for lower abdominal surgeries.Patients were randomly divided into two groups
group A ,B,C ,group A received intrathecal neostigmine 50 micrograms with 2.5 ml of
0.5% hyperbaric bupivacaine and group B received 50 micrograms of clonidine with
2.5ml of 0.5%  hyperbaric bupivacainegroup C received plain hyperbaric bupivacaine
0.5% 2.5 ml.On the day of surgery IV line secured with 18G cannula, IV midazolam
1mg given as premedication. Patients connected to multiparamonitor showing ECG,
PR ,NIBP and SPO 2 and basal readings recorded. All patients are preloaded with IV
fluids of 10 ml/kg .Under strict aseptic precautions lumbar puncture performed at L3-
L4 space using 25 G spinal needle in right lateral position, the study drugs are injected
into subarachnoid space at the rate of 1ml/3 sec. Patient turned supine immediately
and supplemental oxygen given.
Following parameters are observed
Onset time for sensory block
Onset time for motor block
Level of sensory blockade
Quality of motor blockade
Intraoperative haemodynamics every 5th minute
Duration of postoperative analgesia
Quality of postoperative analgesia and Adverse effects
RESULTS
This study was done to compare the use of neostigmine 50µ , clonidine 50µ
along with 0.5% hyperbaric bupivacaine in spinal anaesthesia in patients undergoing
lower abdominal surgeries in providing postoperative analgesia with stable
haemodynamic status.
A total of 60 patients were randomly allocated into three groups, 20 patients in
each group. Group A received 2.5 ml of 0.5% hyperbaric bupivacaine, Group B
received 50µ of neostigmine with 2.5 ml of 0.5% hyperbaric bupivacaine, Group C
received 50µ of clonidine with 2.5 ml of 0.5% hyperbaric bupivacaine. Various
haemodynamic parameters complications if any were recorded at second minute after
spinal and every 5 minutes till the end of surgery.
The observations were noted as follows
Sensory block mean onset time for Group A is 176.2 ± 6.948, Group B is 96.9 ±
19.472 and Group C is 113.95 ± 14.666.
Motor block mean onset time is Group A is 166.2 ± 7.824, Group B is 96.2 ± 29.243,
Group C is 102.75 ± 29.993 seconds.
Duration of surgical anaesthesia in Group A is 176.2 ± 6.948, Group B is 96.9 ±
19.472 and Group C is 113.95 ± 14.666.
Haemodynamic changes were significant between three groups.
No significant changes were observed with VAS score.
Complications were seen in Group B nausea, vomiting, cough and chest pain and in
Group C bradycardia and hypotension were seen.
CONCLUSION
The observations of this study regarding the sensory and motor block
onset time, duration of sensory and motor block, postoperative analgesia  show that
spinal neostigmine has faster onset in both sensory and motor blockade, but spinal
clonidine has longer duration of sensory and motor blockade, and has good post
operative analgesia.
The findings suggest that the use of clonidine 50µ along with 2.5 ml of 0.5%
hyperbaric bupivacaine in lower abdominal surgeries has an added advantage in
comparison with hyperbaric bupivacaine, as it provides longer duration of sensory and
motor blockade, faster onset time of sensory block and good post operative analgesia,
promotes early ambulation, shorter duration of hospital stay and thus reducing
postoperative morbidity. Also it avoids multidrug exposure and its side effects.
This study concluded that spinal clonidine 50µ along with 0.5% hyperbaric
bupicaine is better than 0.5% hyperbaric bupivacaine alone as a effective adjuvant ,
providing good postoperative analgesia.
  
 
INTRODUCTION 
 
Pain is subjective  in nature and can only be perceived by the sufferer. 
International association of the study of pain (IASP) defined ‘pain as an unpleasant 
sensory or emotional experience which is associated with actual or  potential tissue 
damage or described in terms of such damage’. No two patients, even if they 
having the same operation , will experience same pain. Alleviation of  pain during 
and after surgery plays important role in outcome of the patients.  
As anaesthesiologist effective post operative pain management is an essential 
part in the care of surgical patients. As said by Durate in 1997 ‘post operative pain 
is acute form of pain resulting from surgical injury which causes  inflammation and 
neuronal damage that resolves during the appropriate healing  period’. 
Effective control of postoperative pain can reduce morbidity and mortality  
by providing patient comfort and satisfaction , early mobilization  thus less chances 
of deep venous thrombosis and faster recovery with less likelyhood of  development 
of chronic neuropathic pain at lower cost and less hospital stay. 
Different modalities of management of post operative pain are available 
which includes pharmacological and non pharmacological therapies. Pharmological  
methods include administration of  drugs like opioids , non opioids and adjuvants 
(ketamine , clonidine , neostigmine). 
As most lower abdominal surgeries are commonly performed under spinal 
ansesthesia , adding adjuvants which prolong the duration of analgesia and provide 
  
 
post operative pain relief can be beneficial. As spinal anaesthesia is performed with 
single puncture and single shot technique with convention local anaesthetic agents 
which  will not be able to alleviate postoperative pain,continuous research is going 
on to extend intraoperative analgesia to post operative period. 
Addition of opioids to spinal anaesthesia improves analgesia but the period 
of post operative analgesia lasts only for considerable period. So newer adjuvants 
like clonidine , neostigmine , ketamine  to local anaesthetic agents have been tried 
with varying success rates. Clonidine ,  alpha 2 agonist which is centrally acting and 
neostigmine , anticholinesterase  has been tried for post operative analgesia with 
varying successful rates. 
This study is designed to find the effect of adding clonidine and  neostigmine 
with 0.5% hyperbaric bupivacaine  for spinal anaesthesia in lower abdominal 
surgeries. 
  
  
 
AIMS AND OBJECTIVES 
AIM: 
To study the better adjuvant  for intrathecal bupivacaine to achieve better 
quality regional block with stable haemodynamic status and good postoperative 
pain relief. 
OBJECTIVES: 
The objective of the study is comparative evaluation of clonidine and 
neostigmine with 0.5% hyperbaric bupivacaine in spinal anaesthesia with respect to 
Onset time for sensory block 
Onset time for motor block 
Level of sensory blockade 
Quality of motor blockade 
Intraoperative haemodynamics 
Duration of postoperative analgesia 
Quality of postoperative analgesia and Adverse effects 
  
  
 
ANATOMY 
VERTEBRAL COLUMN: 
           The vertebral column  forms the central pillar of the body. It consist of 33 
vertebrae in total – 7 cervical vertebrae, 12 thoracic , 5 lumbar , 5 sacral and 4 
coccyx. The adult spine has four curvatures – cervical and lumbar  curvature with 
lordosis , thoracic and sacral curvature concave forwards (kyphosis). The thoracic 
and sacral curvatures are primary , present during embryonic period where as 
cervical and lumbar curvatures develope later. These curvatures are produced by 
posture and configuration of bones to themselves. The vertebral column encloses 
vertebral canal which consist of spinal cord and nerves. 
VERTEBRAE: 
A vertebra has following parts – body of vertebra , vertebral arch , processes 
– articular , transverse and spinous , vertebral foramina. The  vertebral bodies are 
separated from each other by intervertebral discs. The vertebral arch consists of 
right and left pedicles  and laminae. At the junction of pedicles and lamina arises 
the transverse process facing laterally. Spinous process of vertebra arises from the 
posterior side. The superior and inferior articular processess projects vertically from 
the vertebral arches and have articular facets. 
LUMBAR VERTEBRA: 
Lumbar vertebrae are 5 in number. The lumbar vertebrae has large vertebral 
body which is kidney shaped. It has a triangular vertebral foramen. It has thick and 
  
 
short pedicles. The lamina is short , broader and stronger and does not overlap each 
other. The transverse process of lumbar vertebrae are slender , has articular facets. 
A mammillary process  projects posteriorly from the superior articular process. The  
spinous process of lumbar vertebrae are thick , oblong and horizontal. The fifth 
lumbar vertebra is the largest , wedge shaped , deeper in front than back , so it 
produces lumbosacral angle. 
SPINAL CORD: 
The spinal canal has spinal cord which is the continuation of medulla 
oblongata and ends below as conus medullaris from which filum terminale descends 
till coccyx. In adults the spinal cord ends at the level of  L1 , in children ends at the 
level of L3. The spinal cord contains a covering called meninges , which has three 
layers – pia mater , arachnoid mater and dura mater from inside out. The pia mater 
is very close to the spinal cord , the arachnoid mater is usually adherent to the dura 
mater. The Cerebrospinal fluid (CSF) is present between the pia mater and the 
arachnoid maters in the subarachnoid space. Spinal cord gives rise to 31 pairs of 
spinal nerves – eight cervical , twelve thoracic , five lumbar , five sacral and one 
coccygeal. Each spinal nerve consist of anterior and posterior spinal nerve roots . 
The lower spinal nerves form cauda equina (horse tail). The cauda equina consist of 
lumbar and sacral nerves bathed in CSF that descends to meet their respective 
foramina. 
The blood supply to the spinal cord and spinal nerve roots is derived from 
single anterior spinal artery and two posterior spinal arteries. The anterior spinal 
  
 
artery , branch from vertebral artery , supplies anterior two third of the spinal cord . 
The posterior spinal arteries , branch from posterior inferior  cerebellar arteries , 
supplies posterior one third. The anterior and posterior spinal arteries receive extra 
blood flow from intercostals arteries in thoracic region and from lumbar arteries in 
lumbar region. The artery of Adamkiewicz , large radicular artery , usually 
unilateral , provides major blood supply to anterior and lower two third of spinal 
cord, arises from aorta. 
ANATOMY OF SUBARACHNOID SPACE: 
The subarachnoid space lies between pia mater and arachnoid mater. This 
space communicates with ventricular system of the brain.  
Contents : 
Spinal nerve roots 
Cerebrospinal fluid 
Denticulate ligaments 
Reticulum of fibers connecting pia mater and arachnoid mater. 
  
 
 
SPINAL ANAESTHESIA: 
Spinal anaesthesia is performed by injecting local anaesthetic agents into 
subarachnoid space by means of lumbar puncture. First spinal anaesthesia was 
performed by J.Leonard Corning ,a New York neurologist in the year 1885, in dogs. 
First spinal anaesthesia in human was performed by August Bier in 1898 using 
0.5% cocaine. 
TECHNIQUE: 
Positioning the patient after getting informed consent plays impotant role in 
spinal anaesthesia. Three types of positioning have been described – lateral 
decubitus , sitting and prone position. Usually spinal anaesthesia is performed in 
lateral decubitus and sitting position. The patient should be asked to flex his or her 
  
 
spine in order to widen the vertebral spaces. The lumbar puncture is usually 
performed at the level of L3 and L4 interspace or L4 and L5 interspace. The line 
that joins the highest point of iliac crests , the intercrestal line , also called line of 
Tuffier. This line usually corresponds to L4 vertebra or L4/L5 space. The 
introduction of spinal needle at this space is appropriate as the spinal cord ends at 
the level of L1 in adults. The entry of needle at the intervertebral space can be 
midline or paramedian approach. 
After infiltration of the preferred intervertebral space with local anaesthetic 
agents , spinal needle is inserted and it passess through following structures before 
puncturing dura mater , where a “pop off ” is felt. 
Skin  
Subcutaneous tissue 
Supraspinous ligament 
Interspinous ligament  
Ligamentum flavum 
After puncturing the dura mater, the stylet of  spinal needle is withdrawn to 
see the cerebrospinal fluid  in the hub of the needle. The local anaesthetic agent is 
injected  after aspirating the CSF. 
  
  
 
MECHANISM OF ACTION OF SPINAL ANAESTHESIA: 
The site of action of local anaesthetic agents in spinal anaesthesia is mainly 
on the nerve roots. The following are blocked after injecting the local anesthetic 
agents into CSF in subarachnoid space – sympathetic pre ganglionic b fibers , 
sensory fibers (Aȕ , Aδ, C fibers) , motor fibers (Aα , AȖ)(differential blockade) . 
PHYSIOLOGICAL EFFECTS OF SPINAL ANAESTHESIA: 
EFFECTS ON CARDIOVASCULAR SYSTEM: 
Spinal anaesthesia produces variable decrease in blood pressure along with 
decrease in heart rate. Usually this effect is due to block of sympathetic fibers 
which innervates arteries and veins. Due to sympathetic blockade, there is both 
venous and arteriolar dilatation causing venous pooling of blood and decreased 
systemic vascular resistance respectively. A high sympathetic block prevents the 
compensatory vasoconstriction and also block the sympathetic cardiac accelerator 
fibers that arises from T1-T4, leading to bradycardia and cardiac arrest due to 
unopposed vagal tone. 
PULMONARY EFFECTS: 
Effect of spinal anaesthesia on respiratory system is very less , as the nerve 
fibers that innervate diaphragm arise from C3-C5. Usually even in patients with 
high thoracic levels, tidal volume remains normal with very little decrease in vital 
capacity. Only in patients with severe respiratory disease, who rely on action of 
accessory muscles of respiration for breathing will have difficulty. 
  
 
EFFECT ON GASTROINTESTINAL SYSTEM: 
Spinal anaesthesia blocks sympathetic fibers that supplies the gut, thereby 
increasing the vagal tone, resulting in small contracted gut with active peristalsis. It 
also decreases hepatic blood flow by decreasing mean arterial pressure.  
EFFECT ON GENITOURINARY SYSTEM: 
Spinal anaesthesia has very little effect on renal function as the blood flow to 
the kidney is maintained due to autoregulatory mechanism. Urinary retention after 
subarachnoid block is common as both the sympathetic and parasympathetic supply 
to the bladder is blocked. So in long duration surgeries it is must to place a urinary 
catheter preoperatively. 
EFFECT ON ENDOCRINE SYSTEM: 
Surgical trauma causes significant neuroendocrine response by activation of 
somatic and visceral nerve fibers. It causes increased serum concentration of 
cortisol , epinephrine , norepinephrine , vasopressin , renin – angiotensin  and also 
increase in oxygen consumption by tissues. Due to this neuroendocrine response 
there is intra operative tachycardia , hypertension , hyperglycemia and increased 
catabolism with decreased immunity. Spinal anaesthesia decreases this stress 
response to surgery thus decreasing intra operative and post operative 
complications. 
  
  
 
FACTORS INFLUENCING SPINAL ANAESTHESIA: 
 POSITION OF THE PATIENT DURING INJECTION OF DRUG: 
  If hyperbaric solution is used , in sitting posture solution gets settled 
down , in lateral position , the side on which the patient lies the drug get 
fixed later in spreads to other side. 
 INTERVERTEBRAL SPACE CHOSEN: 
The higher the intervertebral space chosen , higher will be the level of 
analgesia. It is better to chose L2-L3 space in upper abdominal surgeries , 
L3-L4 space in lower abdominal surgeries , L4-L5 space in perineal 
procedures. 
 VOLUME OF DRUG INJECTED: 
Height of analgesia acquired in spinal anaesthesia is directly 
dependent on the volume of drug injected into the subarachnoid space. 
 BARBOTAGE: 
It is a method of mixing the drug which is to be injected into 
subarachnoid space with volume of cerebrospinal fluid for the purpose of 
dispersion. By barbotage , the concentration and specific gravity of the drug 
injected is reduced thereby decreasing the effect of gravity after injection of 
drug. 
  
  
 
 DOSE OF DRUG: 
Greater the concentration and dose of drug , longer will be the 
duration of analgesia. 
 FORCE AND RATE OF INJECTION OF DRUG: 
Greater the force and rate of injection of the drug , higher will be the 
level of block achieved. A slow and gentle injection will have lower level of 
block . 
 SPECIFIC GRAVITY OF THE DRUG INJECTED: 
Specific gravity of the injected drug will have significant effect on 
spinal anaesthesia. The solution may be hyperbaric , hypobaric or isobaric in 
nature. In hyperbaric and hypobaric solution , the posture of the patient 
during and after the procedure will have great impact. 
 POSTURE OF THE PATIENT AFTER INJECTION OF DRUG: 
If the patient assumes lateral position after giving spinal anaesthesia 
and the curves of spine are without effect , the gravity of solution determines 
the side of analgesia. 
If the patient lies supine after spinal , the  baricity of the drug injected 
and the anatomy of the spine influences the level of spread. 
  
 
If the patient is in lithotomy position , the lumbar curvature is 
obliterated. In this posture the hyperbaric solution moves cephalad and the 
hypobaric solution moves caudally. 
 DURATION OF ANALGESIA: 
Depends on the drug used , bupivacaine addition of additives 
increases the duration of analgesia. 
 FIXATION OF DRUG: 
Depends on the drug used , lignocaine takes 2-5 mins where as 
bupivacaine takes about 3- 15 mins. 
 OTHER FACTORS: 
Age, curvature of spine , intrabdominal pressure , needle direction , 
patient height and pregnancy. 
MECHANISM OF ACTION OF LOCAL ANAESTHETIC AGENTS IN 
SPINAL ANAESTHESIA: 
 The site of action of local anaesthetic agents in spinal anaesthesia is mainly 
on the spinal nerve roots. 
 Local anaesthetic agents acts on the sodium and potassium channels in the 
dorsal horns of nerves and inhibits the generation and propagation of 
nociceptive signals. 
  
 
 Motor block is achieved by inhibiting ion channels in the ventral horns of the 
nerves. 
 Centrally administered local anaesthetic agents acts by blocking calcium 
channels , which causes development of resistance to electrical stimulation 
from nociceptive  afferent fibers. 
ADDITIVES IN SPINAL ANAESTHESIA: 
The aim of adding additives along with local naesthetic agents in spinal 
anaesthesia is to increase the quality of spinal anaesthesia and analgesia. 
 Additives decrease the requirement of local anaesthetic agents. 
 It intensifies and prolong the duration of analgesia 
 Has synergistic action , thus decreasing the dose of drug and side effets of 
individual agents. 
INDICATIONS OF SPINAL ANAESTHESIA: 
 In lower abdominal surgeries – inguinal hernia , appendicectomy  
 Urogenital surgeries 
 Surgeries on lower extremities 
 Gynaecological surgeries – abdominal and vaginal hysterectomy  
 Obstetrical – caesarean section 
 
  
 
CONTRAINDICATIONS FOR SPINAL ANAESTHESIA: 
 Absolute : 
Patient refusal 
Infection at the puncture site 
Coagulopathy and bleeding diathesis 
Platelet less than 1,00,000 
Severe hypovolemia 
Increased intracranial pressure 
Severe Mitral and aortic stenosis 
Patients allergic to local anaesthetic agents 
 Relative  
Patients with pre existing neurological deficit 
Patients with severe spine deformities 
Patients who are not cooperative for the the procedure 
Sepsis  
Stenotic valvular lesions  
  
  
 
COMPLICATIONS OF SPINAL ANAESTHESIA: 
 Early : 
Failure or incomplete block 
Total spinal anesthesia 
High spinal 
Hypotension  
Bradycardia  
Cardiac arrest 
Nausea and vomiting 
Shivering  
 Delayed : 
Backache  
Urinary retension 
Post dural puncture headache 
Nerve root injury and Meningitis 
  
  
 
PHARMACOLOGY 
BUPIVACAINE: 
It is the first amide local anaesthetic agent,long acting agent, synthesised by 
B.A.F Ekenstan in 1957. It was first used clinically by Talivuo and Widman in 
1963.  
CHEMICAL FORMULA: 
2-piperidinecarboxamide, 1-butyl-N-(2, 6- di methyl phenyl)-, mono 
hydrochloride , mono hydrate. 
STRUTURAL FORMULA: 
 
PHYSICAL PROPERTIES: 
pKa is  8.1 
Protein Binding is 95% 
Higher Lipid Solubility  
Molecular weight is 288 
  
 
Aqueous lipid solubility coefficient is 343 
It is a white crystalline powder which is freely soluble in 95 % ethanol, also 
soluble in water, and shows little solubility in chloroform or acetone.  
It has left(S) or right (R) configuration. The available bupivacaine in market 
is racemic mixtures of the enantiomers. The permeability of the drug through dura 
and the movement of bupivacaine through the sodium channel present in the nerve 
membrane are determined by the molecular weight. 
As bupivacaine has high lipid solubility it enhances the speed of onset of 
action and also increases the potency and duration of effect, rapid entry into the 
lipid membrane of the cells and longer duration of action. 
MECHANISM OF ACTION OF BUPIVACAINE: 
Bupivacaine , is the drug that causes reversible interference in the entry of 
sodium into the nerve cell causing decreased membrane permeability and increases 
the threshold for electrical excitability.  It inhibits the generation and conduction of 
nerve impulses by increasing the threshold of excitation in the nerve, also slows the 
propagation of the nerve impulse, and reduce the rate of rise of the action potential.  
Binding affinity of local anaesthetics to sodium channels are stereo specific 
and depends on the state of the sodium channel. 
Sodium channels exist in 3 states - activated (open), inactivated (closed) and 
resting (closed) states, during various phases of the action potential. Bupivacaine  
binds to sodium channels that exist in  inactivated closed state, thus  preventing 
  
 
their change to rested closed and activated open states when  nerve stimulus is 
initiated. 
Bupivacine binds to the sites located on the inner side of the sodium 
channels and obstructs the external openings and maintains the channel in 
inactivated closed state, which is not permeable to sodium, the conduction of nerve 
impulses stops. The use of local anaesthetic agent alone  is less common than the 
use of local anesthetic-opioid combination because of a significant failure rate 
(regression of sensory block and inadequate analgesia) and relatively high incidence 
of hypotension. 
The quality of anaesthesia is related to the diameter, myelination of the nerve 
fibers and conduction velocity of affected nerve fibers. The order of anaesthesia of 
nerve fibers are as follows:  pain , temperature,  touch,  proprioception, and  skeletal 
muscle tone. 
PHARMACOKINETICS: 
 ABSORPTION: 
The rate of absorption of the drug depends on the total dose and 
concentration of drug administered, the route by which it is administration, the 
vascularity of the site in which it is administered, and presence or absence of 
epinephrine in the anaesthetic solution.  
  
 
The onset of action of bupivacaine is fast and long-lasting. The duration of 
action is longer. It is said that there is a period of analgesia that persists even after 
the return of sensation, thus delays the requirement of rescue analgesia. 
 DISTRIBUTION: 
Bupivacaine has high protein binding capacity of about 95% , so the plasma 
concentration of the drug administered will be less. Bupivacaine has a low 
foetal/maternal ratio (0.2-0.4). First pass pulmonary extraction is dose 
dependent.Lipid soluble, non-ionized form of drug enters the foetal blood from the 
mothers circulation. 
Based on the route of administration, bupivacaine gets distributed to all 
tissues in the body, with high concentrations found in organs with high blood 
supply such as the liver, lungs, heart and brain. 
Plasma profile of bupivacaine  has been studied which shows that after direct 
intravenous injection of the drug , a three-compartment distribution is seen. The 
first compartment signifies the rapid intravascular distribution of the drug. The 
second compartment shows the equilibration of the drug in organs  with rich blood 
supply such as the brain, myocardium, lungs, kidneys, and liver. The third 
compartment represents an equilibration of the drug in otissues with less blood 
supply, such as muscle and fat.  
The elimination of drug from the tissues depends mainly on the ability of 
binding sites in the circulation to carry it to the liver where it gets metabolized. 
  
 
After injection of bupivacaine , peak levels of bupivacaine in the blood are 
reached within 30 to 45 minutes, declines to insignificant levels from next 3 to 6 
hours. 
The effect of bupivacaine can be altered by the presence of hepatic or renal 
disease, addition of epinephrine , renal blood flow and the route of administration of 
drug. 
The half-life t1/2(hrs)   : 
Adults : 2.7 hours         Neonates : 8.1 hours 
METABOLISM: 
Bupivacaine is metabolized in the liver through conjugation with glucuronic 
acid. Patients with severe hepatic disease, are susceptible to the potential toxicities. 
The major metabolite of bupivacaine is N-desbutyl bupivacaine. 
EXCRETION: 
Excreted mainly by kidneys .Urinary excretion depends on renal perfusion 
and urinary pH . Only 5% of bupivacaine is excreted unchanged in the urine.  
PHARMACODYNAMICS: 
Bupivacaine when absorbed systemically can produce  central nervous and 
cardiovascular effects. At therapeutic doses, following changes are seen in 
cardiovascular system – abnormality in cardiac conduction, excitability,  
contractility, and peripheral vascular resistance.  
  
 
Due to depression of cardiac conduction and excitability,  atrioventricular 
block, ventricular arrhythmias and even cardiac arrest can occur. Also there is 
decrease in myocardial contractility and peripheral vasodilation leading to 
decreased blood pressure. 
Systemic absorption of bupivacaine  can cause central nervous system 
stimulation, depression or both. Stimulation of central nervous system leads to 
agitation, shivering, tremors and convulsions later depression and coma , finally 
respiratory arrest.  
DOSE: 
The required dose of bupivacaine should be calculated based on -the type of 
procedure to be performed, the anatomical area to be anaesthetized, the vascularity 
of the tissues to be anaesthetized, the number of segments to be blocked, the depth 
of anaesthesia and quality of muscle relaxation required, duration of anaesthesia 
required, individual tolerance and the physical condition of the patient. 
The recommended dose is plain bupivacaine 2mg/kg and with epinephrine 3 
mg/kg. 
USES OF BUPIVACAINE: 
 Spinal anaesthesia (0.5%) 
 Epidural anaesthesia(0.125% - 0.75%) 
 Nerve blocks (0.25 %- 0.5 %) 
  
 
 Local infiltrations (0.25 %) 
 Retrobulbar and peribulbar blocks 
 Caudal anaesthesia 
ADVERSE EFFECTS: 
 Allergic reactions to the drug – usually seen in less than 1 % of the 
individuals , characterized by rash ,urticaria , bronchospasm , laryngeal 
oedema , hypotension. 
 Systemic toxicity – central nervous system toxicity and cardiovascular 
toxicity. Central nervous system toxicity occurs when the serum plasma 
concentration of the drug is 4.5 – 5.5 µ/ml. Characterized by circumoral 
numbness , restlessness, vertigo, tinnitus, slurred speech, twitching of 
facial muscles and convulsions. 
Cardiovascular toxicity occurs when the plasma concentration of the drug is 
above 8µ/ml. Usually seen after accidental intravenous injection of bupivacaine. 
Characterized by sudden hypotension , atrioventricular block ,dysrythmias and 
sudden cardiac arrest. Cardiac arrest caused due to bupivacaine is very difficult to 
revive. Bertylium  and intralipids can be used to treat both cardiovascular and neuro 
toxicity. 
  
  
 
CONTRAINDICATIONS FOR BUPIVACAINE USE: 
 Known hypersensitivity to the drug 
 Heart block 
 Severe Sepsis  
 Intravenous regional anaesthesia – Biers block 
 Obstetrical paracervical block 
NEOSTIGMINE: 
Neostigmine is a parasympathomimetic drug which act as reversible 
Acetylcholine inhibitor. It is first synthesised by Aeschlimann and Reinert in 1931. 
CHEMICAL FORMULA: 
3-dimethyl amino phenol with N- di methyl carbamate. 
STRUCTURAL FORMULA: 
 
  
 
MECHANISM OF ACTION OF NEOSTIGMINE: 
Neostigmine acts by inhibiting  the hydrolysis of acetylcholine by 
competitively binding to the esteric site of acetylcholinesterase. It causes 
accumulation of acetyl choline there by enchancing he cholinergic action and 
facilitates impulse transmission.  
Neostigmine when given in subarachnoid block that is spinal anaesthesia it 
gets absorbed into cerebrospinal fluid. Neostigmine acts both on the muscarinic and 
nicotinic receptors. In spinal , neostigmine acts on the Lamina 2 Substantia  
Gelatinosa of Ronaldi and on Lamina 3 and 4, and cause stimulation of muscarinic 
receptors M1 and M2. 
PHYSICAL PROPERTIES OF NEOSTIGMINE: 
Molecular weight - 303.1 
Protein binding – 15% -25% 
PHARMACOKINETICS: 
 ABSORPRION: 
When given in spinal anaesthesia ,it gets absorbed rapidly in the CSF, 
but the gastrointestinal route of absorption is poor. Intravenously 
administered neostigmine gets absorbed within minutes and the onset action 
time is 1-2 minutes. When given through intramuscular route the onset of 
action takes 20 – 30 minutes. 
  
 
 DISTRIBUTION: 
Neostigmine is only 15 -25% protein bound. It is bound to albumin. 
 HALF LIFE : 
Half life is 50 -90 minutes. 
 METABOLISM: 
Neostigmine is metabolized by liver with microsomal enzymes. It also 
undergoes hydrolysis by cholinesterase. 
 EXCRETION: 
Neostigmine , upto 50%  is excreted unchanged in urine. 
Total body clearance is between 1.14 and 16.7 ml/kg/min. 
DOSE : 
 For reversing the effect of neuromuscular blocking agents , non depolarising 
muscle relaxants , the dose usually used is 40-80µ/kg. Usually atropine is 
given before giving neostigmine to prevent bradycardia. Neostigmine should 
be given slowly and dose should be titrated based on the response using 
nerve stimulator. 
 In myasthenia gravis , neostigmine is given as oral tablets , dose ranges from 
50 – 300 mg per day. 
  
  
 
USES: 
 Reversing the non depolarising block 
 Treatment of myasthenia gravis 
 Prevention and treatment of postoperative urinary retension 
ADVERSE EFFECTS: 
 Hypersensitivity  
 Arrhythmia , AV blocks and cardiac arrest 
 Convulsion 
 Gastrointestinal cramps 
 Urinary frequency 
CONTRAINDICATIONS: 
 Known allergy to drug 
 Intestinal or urinary tract obstruction 
 Bronchial asthma 
 Patients with cardiac arrhythmias 
 Neostigmine should be used with caution in patients with epilepsy , 
hyperthyroidism , peptic ulcer , recent myocardial infarction , av blocks. 
  
  
 
DRUG INTERACTIONS: 
 Neostigmine  prolongs the phase 1 block produced by depolarising muscle 
relaxants. So it should not be used to reverse this type of blocks. 
 Neostigmine has additive effects when used with opioids. 
 Neostigmine also has additive effects with alpha adrenoreceptor agonists 
like clonidine. 
CLONIDINE: 
Clonidine is a centrally acting alpha 2 adrenergic agonist and also 
imidazoline receptor agonist , having sympatholytic action. Clonidine is  
synthesised by Boehringer Ingelheim in 1966. 
CHEMICAL FORMULA: 
N-(2,6 -dichlorophenyl) -4,5 dihydro -1H imidazol -2 amine 
STRUCTURAL OF CLONIDINE: 
 
  
 
MECHANISM OF ACTION: 
Clonidine is selective partial agonist of alpha 2 adrenergic receptors. 
Clonidine when administered intrathecally , that is in spinal anaesthesia , gets 
absorbed quickly in cerebrospinal fluid and acts on the post synaptic alpha 2 
receptors(stimulation) in Substantia Gelatinosa present in dorsal horn of the spinal 
cord. Clonidine also has intrinsic property to block the conduction in C and Aδ 
fibers. 
Clonidine stimulates alpha 2 receptors in brain and spinal cord and causes 
decrease in sympathetic outflow from the central nervous system resulting in 
decreased blood pressure and heart rate. 
The anatomic site of action of clonidine is on the receptors present in spinal 
dorsal horn and supraspinally in nucleus coereleus in pons. The mechanism of 
sedative effects of clonidine is due to hyperpolarization of exitable neurons in 
nucleous coereleus. The analgesic property of clonidine has multiple mechanisms 
acting on brain , brain stem and spinal cord .The action at the spinal level are by 
activation of descending medullospinal noradrenergic pathways and by reduction of 
spinal sympathetic outflow at presynaptic ganglions. It also suppresses the 
generation of action potential in spinal dorsal horn cells. Clonidine also acts by 
opening the potassium channels , the mechanism by which local anaesthetic agents 
acts. 
Clonidine has specificity towards binding to alpha 2 receptors in the 
vasomotor centre in brain stem and this binding causes decrease in presynaptic 
  
 
calcium , inhibiting release of norepinephrine. Clonidine exerts its antihypertensive 
effects by acting as imidazoline I1 receptor agonist. 
PHYSICAL PROPERTIES: 
Molecular weight   230 
Protein binding   20- 40 % 
pka       8 
PHARMACOKINETICS: 
The pharmacokinetics of clonidine is dose proportional which lies in the 
range of 100 – 600 mcg. On oral administration clonidine is absorbed 70 -90% and 
the peak plasma clonidine levels are reached at 1-3 hours. After intravenous 
injection of clonidine , it shows biphasic disposition . the distribution half life is 20 
minutes and that of elimination is 12-16 hours. 
Clonidine crosses blood brain barrier and also crosses placenta. The half life 
is increased in patients with severe renal failure. The absorbed drug , after oral 
administration , of which 50% is recovered unchanged in urine. Clonidine is 
metabolized in liver and excreted through kidneys. 
DOSAGE: 
 For spinal anesthesia as an adjuvant dose ranges from 25µ - 150µ ,1-2 µ/ 
kg .Different doses have different effects which includes hypotension , 
sedation , bradycardia , long duration of analgesia. 
  
 
 Anti hypertensive – usually administered orally. Usually started as 0.1 
mg tablet twice a day and titrated by increasing the dose by 0.1 mg 
weekly after observing the response of the patient to the drug. 
USES: 
 As adjuvant in spinal and epidural analgesia 
 Premedication agent 
 Antihypertensive agent  
 In Attention Deficit Hyperactivity Disorder 
 Chronic diarrhoea 
 Glaucoma 
 Diagnosing pheochromacytom – clonidine suppression test 
 Migraine  
 Postmenopausal flushing 
 Opioid withdrawal 
 Anxiety disorder  
CLONIDINE WITHDRAWAL: 
As clonidine acts by decreasing the sympathetic outflow and there by 
decreasing the blood pressure , sudden withdrawal causes rebound hypertension due 
to sudden increase in sympathetic outflow. So clonidine therapy should be  tapered 
  
 
gradually to minimize the hypertension. Treatment of clonidine withdrawal 
hypertension consist of  beta blockers and readministration of clonidine to decrease 
blood pressure and gradually decrease it. 
ADVERSE EFFECTS: 
 Cardiovascular : bradycardia , hypotension , raynaud’s phenomenon , AV 
blocks. 
 Central nervous system : insomnia , nervousness , vivid dreams , delusion 
and hallucinations 
 Dermatological : allergic reaction , atopic eczema , rash , urticaria 
 Gastrointestinal :abdominal pain , vomiting , transient changes in liver 
function tests , acute pancreatitis , pseudo obstruction of bowel. 
 Haematological : thrombocytopenia 
 Erectile dysfunction. 
CONTAINDICATIONS: 
 Patient with known hypersensitivity reaction 
 Patients with sinoatrial disease and atrioventricular blocks. 
DRUG INTERACTIONS: 
 Clonidine increases the CNS depression effects of alcohol , antidepressants 
and sedative drugs. 
  
 
 When clonidine is used along with cardiac drugs like digitalis , calcium 
channel blockers and beta blockers monitoring of heart rate is mandatory as 
it precipitates braycardia. 
 Clonidine when used in high doses along with haloperidol can precipitate 
arrhythmias. 
  
  
 
REVIEW OF LITERATURE 
 
Elia et al (from april 2010 to jan 2011) , conducted a study including 1,445 
patients , using intrathecal clonidine  as adjuvant to bupivacaine  and found that 15 
– 150 µ prolonged  , the time to two segment regression (mean 14 to 75 min), delay 
in regression time to L2 , the time to need for first rescue analgesic (median 101 
min, range 35 – 310 min ) and motor block( median 47 minutes , range 6 - 131) was 
extended without any relation to dose. Increased incidence of arterial hypotension 
without the effect of dose and the risk of bradycardia was unchanged. 
Marrivirta et al (2010), in 60 ambulatory patients undergoing , added 75µ 
of clonidine to 6 mg spinal hyperbaric bupivacaine vs 6 mg bupivacaine alone. This 
study showed that motor block was prolonged in patients who received clonidine. 
Also these patients need more vasopressor and less post operative pain. 
Yoganarasimha and co-worker in 2014 , compared intrathecal clonidine 
75µ versus intrathecal neostigmine 50µ as adjuvant drug for spinal anaesthesia 
0.5% hyperbaric bupivacaine 12.5 mg ;analgesia was prolonged with clonidine 
(362+/- 36 mins) compared with neostigmine (300+/-25 min). 
Kanazi et al in 2006 , compared ‘clonidine γ0 µ versus dexmedetomidine 
3µ added to 12 mg of spinal hyperbaric bupivacaine , versus bupivacaine alone in 
60 transurethral resection of prostrate. Patient treated with alpha 2 agonist has rapid  
onset time of motor block and took longer time for sensory and motor regression . 
The mean time for sensory regression to reach level of S1 segment was 303+/-75 
  
 
min for dexmedetomidine , 272 +/- 38 min in clonidine group , 190+/- 48 min in 
patients with bupivacaine alone.the regression of motor block to bromage 0 was 
250+/- 76 min.  
Andrieu et al in 2004 compared intrathecal morphine 4µ/kg  with and 
without clonidine 4µ/kg  in patients undergoing radical retropubic prostatectomy . 
adding clonidine to spinal morphine reduced intraoperative use of sufentanil , 
prolonged time for first rescue analgesia . 
Strebel et al in 2004, compared three doses of clonidine (37.5,75 and 150 
μg) added to spinal 0.5% bupivacaine 18 mg in 80 orthopaedics patients. In patients 
receiving intrathecal clonidine  the duration of sensory block (regression below the 
level L1) was increased in patients receiving: γ11±101 min in γ7.5 μg (+8%), γβ5 
±69 min in 75 μg (+1γ%), and γγ7±78 min in those patients who received 150 μg 
(+17%) (estimated parameter for dose 0.23 [95% confidenceinterval-0.05-0.50]) 
versus control group 288 ±62 min. Time to first analgesic request was also 
prolonged: 343 ±75 min (+16%), 381±117 min (+29%), and 445±136 min (+51%) 
(estimated parameter for dose 1.02 [95% confidence interval 0.59-1.45]), 
respectively compared to control group 295±80 min. Hemodynamic stability of the 
was maintained throughout the procedure and they found no differences in sedation 
level’.  
Tuijl et al, in 2013 investigated the effect of 0, 15 and γ0 μg of clonidine 
added to 5 mg of 0.5% hyperbaric bupivacaine on the prolongation of motor block, 
analgesia and ability to void after knee arthroscopy. They found that clonidine 
  
 
increased the duration of  motor block duration by 25 and 34 min respectively. They 
also found better analgesic quality, and the mean time for spontaneous voiding was 
increased up to 18 and 44 min respectively. 
Mahendru et al in 2013, conducted a prospective studystating that ‘adding 
clonidine γ0 μg, vs. dexmedetomidine 5 μg, vs. Fentanyl β5 μg to 1β.5 mg spinal 
hyperbaric bupivacaine in cases of lower limb surgeries. They discovered that 
dexmedetomidine prolonged significantly sensory and motor block compared to 
clonidine, fentanyl and bupivacaine alone. The mean time of two segment sensory 
block regression was 147±21 min with dexmedetomidine, 117±22 with clonidine, 
119±23 in those patients receiving fentanyl, and 102±17 in bupivacaine alone (p> 
0.0001). The time taken for regression of motor block to reach modified Bromage 
scale grade 0 was 275±25, 199±26, 196±27, 161±20 respectively (p > 0.0001). The 
haemodynamic status of the patient was maintained. In patients aged 60 years or 
more who are undergoing orthopaedic surgeries for lower limb, intrathecally 
clonidine 15 μg or γ0 μg was given along with 9 mg hyperbaric bupivacaine, which  
potentiated the sensory block levels and duration of analgesia without affecting the 
trend of systolic blood pressure as compared to bupivacaine alone. Clonidine in 
doses of γ0 μg however facilitated the spread of sensory block to unexpectedly 
higher dermatomes for a longer time. Spinal postoperative analgesia can be 
improved by epidural infusion of  40 μg/h mixed with ropivacaine 4 mg/h-1in 
patient undergoing hip arthroplasty. 
  
 
Gehling et al in 2008 ,studied 45 patients who are undergoing hip or knee 
replacement surgery with 15 mg of  bupivacaine spinal anaesthesia and calculated a 
mean time for the first opioid request was for placebo group are 10.3±7.9 h, for 0.1 
mg morphine group it was βγ.0±γ.9 h and for 0.1 mg morphine+50 μg clonidine 
group it was β1±6.9 h. Combination of pethidine 0.75 mg/kg  and clonidine 75 μg 
in spinal anaesthesia provided good intraoperative anaesthesia for total hip 
replacement, but similar to plain isobaric 0.5% bupivacaine’. 
Mercier et al in 1998 ,compared sufentanil 5 μg and clonidine γ0 μg versus 
sufentanil 5 μg alone given intrathecally to reduce pain in the first stage of labour, 
they found  that clonidine potentiate labour analgesia and side effects such as 
hypotension, maternal pruritus and sedation were equal in both groups. 
Gautier et al in 2002 ,studied about the use of γ0 μg of intrathecal clonidine 
with 5 μg of intrathecal sufentanil in labour analgesia. He found out that there is 
increase in the duration of analgesia during the first stage without any maternal or 
fetal sideeffects. 
Chiari et al in β011 ‘conducted a study by using  clonidine alone in spinal 
anaesthesia for relieving pain during labour; in 36 parturients with cervical dilation 
< 6 cm; they compared 50, 100, and β00 μg intrathecal clonidine and found that 
labour pain was significantly reduced in all patients, analgesia duration was 
significantly longer with β00 μg (median 14γ; range of means75-210 min), with 
100 μg (median 118; range of means 60-180 min) and using 50 μg (median 45; 
  
 
range of means 25-150 min).Hypotension was associated with β00 μg and the need 
of intravenous ephedrine more often than in the other group’. 
Rochette et al, studied 75 patients which were injected with increasing doses 
of clonidine (0.β5, 0.5, 1 y β μg/kg) with plain spinal bupivacaine 0.5% (1 mg/kg) 
and concluded that clonidine 1 μg/kg produces improvement in spinal anaesthesia 
duration without significant side effects. Dose of β μg/kg produced transient 
hypotension. In a randomized investigation with 45 children aged 6 to 15 years, 
clonidine βμg/kg prolonged motor block and improved postoperative analgesia. 
Hypotension and bradycardia were 54% and 30% respectively. 
Lauretti GR et al in 1998 , studied in 45 patients the dose response of spinal 
morphine and intrathecal neostigmine,  for postoperative analgesia in patients 
undergoing anterior and posterior vaginoplasty. 24-h visual analog scale score was 
analysed in both the groups. In group who receives spinal neostigmine the VAS 
score was significantly lower than in those who received morphine alone (P = 0.00). 
The durations of postoperative analgesia were longer for all patients in group 
receiving neostigmine compared with other groups. The incidence of nausea and 
vomiting was not increased in neostigmine group. 
Hood DD, Mallak KA, Eisenach JC, Tong C in 1996, studied ‘interaction 
between spinal neostigmine and epidural clonidine in human volunteers. A total of 
58 volunteers received spinal injection of 5% dextrose in normal saline or 
neostigmine (50, 100, or 200 micrograms in D5NS), followed in 1 h by epidural 
saline or clonidine . Visual analog scale score for  pain to a noxious cold stimulus, 
  
 
nausea, weakness, sedation, and other safety variables was measured before and at 
specified intervals after drug administration.The first 21 volunteers who received 
spinal neostigmine rather than D5NS received the drug while in the sitting position, 
and had none-to-minimal analgesia 1 h later. The remaining volunteers received the 
drug in the lateral position, and demonstrated dose-dependent analgesia in the foot 1 
h later. Epidural clonidine also caused dose-dependent analgesia. The combination 
of neostigmine and clonidine resulted in an additive enhancement for analgesia, but 
there is no enhancement of each drug's side effects, and also decreases clonidine-
induced hypotension. Neostigmine injected into subjects in the lateral position 
diminished clonidine-induced reductions in blood pressure and plasma 
norepinephrine’. 
Pan PM, Huang CT, Wei TT, Mok MS in 1998, conducted a study that 
states ‘comparison of the analgesic effect of intrathecally administered neostigmine 
and clonidine along with bupivacaine in spinal anaesthesia for patients undergoing 
caesarean section. After explaining about the purpose of study and getting consents, 
80 patients  who were posted for cesarean section using spinal anesthesia were 
enrolled by a double-blind randomized design into four groups: bupivacaine group - 
received intrathecal  ,10 mg of  bupivacaine; bupivacaine + neostigmine group - 
received , 10 mg of bupivacaine + 50 microg of neostigmine; bupivacaine + 
clonidine group  received - 10 mg of bupivacaine + 150 microg of clonidine; and 
bupivacaine + both (n = 21) received - 10 mg of bupivacaine + 50 microg of 
neostigmine + 150 microg of clonidine. The level spread of anesthesia , maximum 
duration of analgesia and motor block,  pulse rate , blood pressure , oxygen 
  
 
saturation, and side effects were recorded for 14 hours post injection. Fifty 
milligrams of intramuscular meperidine was given as a rescue analgesic whenever 
patient's pain score was greater than 5/10 by the visual analog scale. 
 Bupivacaine and the both group had a higher maximum spread of anesthesia 
of 23.3 +/- 2.9 segments than bupivacaine alone group of 20.5 +/- 2.9 segment. 
Bupivacaine + both group showed a delayed onset of postoperative pain of 6.5 +/- 
1.5 hours as compared to bupivacaine group of 1.3 +/- 0.6 hours. The pain score in 
bupivacaine + both group was significantly lower than that of bupivacaine alone 
group during the first 10 hours. The 24-hour meperidine consumption also was 
lower in bupivacaine + both group than that of bupivacaine group. However, motor 
block was significantly prolonged from 3.5 +/- 1.1 hours in bupivacaine group to 
7.1 +/- 1.6 hours in bupivacaine + both group. In addition, other side effects such as 
nausea and vomiting and dizziness were significantly increased in bupivacaine + 
both group’. 
Klamt JG. Sluttitel A, Garcia IV, Prado WA in 1997 , conducted a study 
on postoperative analgesic effect of intrathecal neostigmine and its influence on 
spinal anaesthesia. 
  
  
 
MATERIALS AND METHODS 
 
This study was a prospective randomized double blinded control Trial.   In 
this study, 60 patients  from the Department of General Surgery and Department of 
Obstetrics and Gynecology , Chengalpattu Medical College Hospital was analysed 
.The study was done over a period of one year .Institutional ethical Committee 
approval obtained. Patients who were posted for lower abdominal surgery in the age 
group of 20 – 60 years were counselled about the purpose of study. The procedure 
was explained to the patient in their own language. Informed consent was obtained. 
Patients who fulfil the inclusion criteria and those who gave consent were then 
randomly allocated to one of the study groups based on computerized randomized 
list. 
INCLUSION CRITERIA: 
 1. Age 18 to 60 years 
 2. ASA I and II 
 3. Patient posted for lower abdominal surgeries 
 4. Patient who are fit for spinal anaesthesia 
EXCLUSION CRITERIA: 
 Hypersensitivity to  bupivacaine , neostigmine and clonidine 
 Hemodynamic instability 
  
 
 Patients with ischemic heart disease 
 Infection at the site of lumbar puncture   
 Patient refusal 
 On anticoagulants 
 Bronchial asthma  
 Neuropathy   
 Bleeding disorders 
 Psychiatric illness  
 Morbidly obese  
MATERIALS REQUIRED FOR THE PROCEDURE: 
1. 25 G Quinckes spinal needle 
2. 5 ml sterile syringes 
3. Hypodermic needles 18 G 
4. Bowl, Sponge holding forceps, gauze, sterile towel, Chlorhexidine 
solution. 
5. Sterile gown, Gloves, Cap & Mask 
6. Local anaesthetic solution – 2% Lignocaine with adrenaline 
7. 0.5% hyperbaric Bupivacaine , neostigmine , clonidine  
8. Boyle’s apparatus and oxygen cylinder 
  
 
9. Emergency kit with working laryngoscope, endotracheal tubes of 
appropriate size, airway, suction apparatus with suction catheter. 
10. Emergency drugs Inj. Adrenaline, Inj. Atropine, Inj.Thiopentone, 
Inj.Succinylcholine 
11. Monitor for continuous monitoring of Pulse Rate, Oxygen saturation, 
Non-invasive blood pressure, ECG, Respiratory rate. 
METHODOLOGY: 
An 18G IV cannula was inserted and patient was started on an infusion of 
Ringer lactate solution at 10ml/kg and the patient connected to multi para monitor. 
The patient was made to lie in right lateral position, with a pillow.  
Under strict aseptic precautions, the skin over the lumbar region was cleaned 
with the povidone-iodine solution and the area was covered with sterile drape. The 
space between the L3and L4 space was identified and the skin over that area was 
infiltrated with 2% lignocaine.The skin was pierced with 25G Quinckes needle at 
L3 – L4 intervertebral space. The Quinckes needle was advanced with the bevel 
facing upward till it pierces the dura. The stylet was removed and then observed for 
cerebrospinal to flow. After careful aspiration of cerebrospinal fluid , the desired 
drug is injected into subarachnoid space. Then the patient was made into the supine 
position immediately.  
Vital signs were monitored at 2nd minute and then every 5 minutes till 
completion of surgery. The surgery was started after obtaining adequate sensory 
block and adequate analgesia and surgical anaesthesia till T6 level assessed by 
  
 
pinprick test. Vitals were monitored in the postoperative period. Pain was assessed 
using VAS (visual analogue scale) at the end of surgery during the recovery period 
when patient was awake. At the end of the surgery, motor block was assessed using 
modified Bromage scale for both lower limbs. 
The study concluded at the end of the surgery. Both the patient and the 
anaesthesiologist who gave anaesthesia were blinded to the study solutions. 
Following parameters are noted: 
1. Heart Rate 
2. Non invasive Blood Pressure 
3. Oxygen saturation 
4. Respiratory Rate 
5. Sensory Block 
a. Onset time 
b. Duration 
c. Maximum level of sensory block 
6. Motor Block 
a. onset time 
b. quality of motor block 
7.  Rescue Analgesia 
8.  VAS score 
9.  Postoperative Analgesia  
  
 
Pain assessed using visual analogue scale: 
 
‘Assessment of motor block by using modified Bromage scale 
Grade 0  No motor block 
Grade 1 Inability to raise extended leg, able to move knees and feet 
Grade 2  Inability to raise extended leg and move knee, able to move feet 
Grade 3 Complete motor block of the lower limbs. 
 
 
 
  
 
 
STATISTICAL ANALYSIS 
 
The statistical analysis was done using SPSS (Statistical package for social 
sciences) version 16 for windows. Descriptive statistics are presented as mean± 
1SD. Bar and line diagrams are drawn as and when required. Chi square test for 
association is used for comparison of categorical variables between treatment 
allocations. 
RESULTS AND OBSERVATIONS: 
Study includes 60 patients who were posted for lower abdominal surgeries. 
They were randomly allocated to either Group-A ( 0.5% hyperbaric bupivacaine) or 
Group-B (0.5% hyperbaric bupivacaine with 50µ neostigmine) , Group – C (0.5% 
hyperbaric bupivacaine with clonidine 50µ).The patient characteristics such as age, 
sex ,weight, ASA classification , comorbid conditions of the patients are noted. 
The outcomes measured were onset of  sensory block , duration of the block, 
level of block achieved, haemodynamic status of the patient intra operatively, 
duration and quality of motor block, Rescue analgesia, VAS score and 
complications . 
  
  
 
CHARACTERISTICS OF THE PATIENT: 
 AGE DISTRIBUTION: 
The average age between the three groups, does not varies much. The mean 
age of Group A is 41.45 ± 12.45, Group B is 43.4 ± 8.923, Group C is 39.15 ± 
11.811. The difference between the groups in age distribution was not statistically 
significant. The p value is 0.489. 
 
Descriptive Groups N Mean Std. Deviation Std. Error Minimum Maximum 
Age 
A 20 41.45 12.458 2.786 18 59 
B 20 43.4 8.923 1.995 25 62 
C 20 39.15 11.811 2.641 20 57 
Total 60 41.33 11.118 1.435 18 62 
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 WEIGHT : 
The average weight of the patient in Group A is 60.1± 6.593  kg , Group B is 
61.35 ± 9.213  and Group C is 61.25 ± 7.247 . The difference between the three 
groups in weight of the patients were not significant as the p value is 0.852. 
 
Descriptive Groups N Mean Std. Deviation Std. Error Minimum Maximum 
WT 
A 20 60.1 6.593 1.474 47 71 
B 20 61.35 9.213 2.06 40 76 
C 20 61.25 7.247 1.62 49 78 
Total 60 60.9 7.653 0.988 40 78 
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 GENDER DISTRIBUTION: 
In Group A consist of 7 male patients and 13 female patients. Group B has 9 
male patients and 11 female patients. Group C had 14 male patients and 6 female 
patients. The gender distributions of all three groups are comparable. 
 
Sex 
Group A Group B Group C 
Frequency Percent Frequency Percent Frequency Percent 
Male 7 35 9 45 14 70 
Female 13 65 11 55 6 30 
Total 20 100 20 100 20 100 
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 DURATION OF SURGERY: 
The mean duration of surgery were comparable between the three groups. 
The mean duration of surgery in Group A is 53.4 ± 8.217 , Group B is 66.25 ± 
18.416 , Group C is 66.5 ± 14.336. The p value is 0.007 and is statistically 
significant. 
Descriptives Groups N Mean Std. Deviation 
Std. 
Error Minimum Maximum 
Duration of 
surgery 
A 20 53.4 8.217 1.837 35 70 
B 20 66.25 18.416 4.118 30 110 
C 20 66.5 14.336 3.206 45 90 
Total 60 62.05 15.336 1.98 30 110 
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 ONSET OF SENSORY BLOCKADE: 
The mean onset time of sensory block in Group A is 176.2 ± 6.948, Group B 
is 96.9 ± 19.472 and Group C is 113.95 ± 14.666. The p value is statistically 
significant (p = 0.0001) between the three groups. 
 
Descriptives Groups N Mean Std. Deviation Std. Error Minimum Maximum 
ONSET 
A 20 176.2 6.948 1.554 164 186 
B 20 96.9 19.472 4.354 68 140 
C 20 113.95 14.666 3.28 80 154 
Total 60 129.02 37.258 4.81 68 186 
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 MAXIMUM LEVEL OF SENSORY BLOCK ACHEIVED: 
The levels of sensory block achieved between the groups were not 
statistically significant. The p value is 0.199.  
 
Descriptives Groups N Mean Std. Deviation Std. Error Minimum Maximum 
SPREAD 
A 20 5.7 1.174 0.263 4 8 
B 20 5.95 1.395 0.312 4 8 
C 20 6.35 0.745 0.167 6 8 
Total 60 6 1.15 0.148 4 8 
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 ONSET TIME OF MOTOR BLOCK: 
The mean onset time for motor block in each groups were as follows: Group 
A is 166.2 ± 7.824, Group B is 96.2 ± 29.243, Group C is 102.75 ± 29.993. 
 
Descriptives Groups N Mean Std. Deviation 
Std. 
Error Minimum Maximum 
MOTOR 
BLOCK 
A 20 166.2 7.824 1.75 150 178 
B 20 96.25 29.243 6.539 60 180 
C 20 102.75 29.993 6.707 60 190 
Total 60 121.72 39.975 5.161 60 190 
 
 
 
 
0
20
40
60
80
100
120
140
160
180
A B C
MOTORBLOCK
166,2 
96,25 
102,7 
  
 
 INTRAOPERATIVE HAEMODYNAMICS: 
In all the patients who are subjected to the study, the hemodynamic status 
was monitored. The parameters monitored were pulse rate, systolic blood pressure , 
diastolic blood pressure , oxygen saturation, the reading taken after two minutes 
after spinal anaesthesia there after vitals monitored every fifth minute till the end of 
surgery. 
 PULSE RATE:  
Variables Group N Mean Std.  Deviation Std. Error Minimum Maximum F Sig. 
PR 
PREOP 
A 20 78.9 9.968 2.229 60 100 
1.394 0.256 
B 20 83.5 14.468 3.235 60 124 
C 20 84.55 8.947 2.001 68 104 
Total 60 82.32 11.459 1.479 60 124 
PR2 
A 20 84.45 7.185 1.607 74 96 
3.931 0.025 
B 20 90.3 11.815 2.642 74 124 
C 20 81.9 9.586 2.143 64 107 
Total 60 85.55 10.185 1.315 64 124 
PR5 
A 20 82.45 8.338 1.864 68 96 
8.464 0.001 
B 20 88.8 11.848 2.649 72 119 
C 20 75.75 9.591 2.145 63 103 
Total 60 82.33 11.229 1.45 63 119 
PR10 
A 20 83.05 7.366 1.647 66 92 
13.065 0.0001 
B 20 87.3 10.006 2.237 70 111 
C 20 73.15 9.366 2.094 59 102 
Total 60 81.17 10.663 1.377 59 111 
PR15 
A 20 84.55 9.768 2.184 64 100 
10.305 0.0001 
B 20 83.9 12.143 2.715 60 110 
C 20 71.55 8.338 1.864 57 92 
Total 60 80 11.704 1.511 57 110 
PR20 
A 20 82.7 10.408 2.327 62 104 
12.764 0.0001 
B 20 82.45 10.47 2.341 57 99 
C 20 68.8 8.912 1.993 54 90 
Total 60 77.98 11.775 1.52 54 104 
PR25 
A 20 81.1 10.809 2.417 61 102 
10.927 0.0001 
B 20 83.15 9.778 2.186 58 100 
C 20 70.3 7.02 1.57 59 86 
Total 60 78.18 10.798 1.394 58 102 
PR30 
A 20 81.65 10.52 2.352 62 94 
12.864 0.0001 
B 20 81.25 8.46 1.892 60 93 
C 20 69.45 6.468 1.446 54 83 
Total 60 77.45 10.234 1.321 54 94 
PR35 
A 20 82.15 8.928 1.996 63 96 
12.436 0.0001 
B 20 80.9 7.907 1.768 61 96 
  
 
Variables Group N Mean Std.  Deviation Std. Error Minimum Maximum F Sig. 
C 20 70.7 6.937 1.551 53 85 
Total 60 77.92 9.383 1.211 53 96 
PR40 
A 20 81.15 8.061 1.802 62 98 
12.1 0.0001 
B 20 80.55 7.38 1.65 64 90 
C 20 71 6.432 1.438 57 89 
Total 60 77.57 8.589 1.109 57 98 
PR45 
A 20 79 7.064 1.579 62 91 
15.639 0.0001 
B 20 80.5 6.573 1.47 68 91 
C 20 69.75 6.077 1.359 55 85 
Total 60 76.42 8.053 1.04 55 91 
PR50 
A 20 78.45 7.395 1.654 62 94 
17.941 0.0001 
B 20 80.7 5.639 1.261 72 89 
C 20 69.2 6.144 1.374 54 80 
Total 60 76.12 8.074 1.042 54 94 
PR55 
A 20 77 8.105 1.812 60 93 
14.308 0.0001 
B 20 82.05 6.1 1.364 72 94 
C 20 70.25 6.64 1.485 58 85 
Total 60 76.43 8.432 1.089 58 94 
PR60 
A 12 79.33 9.018 2.603 60 96 
8.164 0.001 
B 17 81.35 4.676 1.134 72 90 
C 16 72.5 5.967 1.492 58 79 
Total 45 77.67 7.492 1.117 58 96 
PR70 
A 7 78.43 8.886 3.358 60 85 
4.184 0.04 
B 10 80.8 5.574 1.763 73 88 
C 9 72.78 6.942 2.314 61 87 
Total 26 77.38 7.627 1.496 60 88 
 
 
 
The preoperative pulse rate in three groups are not significant statistically 
where as the pulse rate after tenth minute of spinal anaesthesia were significant 
statistically. 
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 SYSTOLIC BLOOD PRESSURE: 
Variables Group N Mean Std.  Deviation 
Std. 
Error Minimum Maximum F Sig. 
SB 
PPREOP A 20 124.35 10.07 2.252 110 159 0.301 0.741 
 
B 20 126.35 13.124 2.935 108 154 
  
 
C 20 123.7 10.322 2.308 106 139 
  
 
Total 60 124.8 11.123 1.436 106 159 
  
SBP2 A 20 122.3 8.467 1.893 108 150 1.523 0.227 
 
B 20 124.6 11.98 2.679 104 148 
  
 
C 20 118.45 12.857 2.875 93 140 
  
 
Total 60 121.78 11.362 1.467 93 150 
  
SBP5 A 20 118.7 8.578 1.918 104 147 2.715 0.075 
 
B 20 122.05 10.185 2.277 102 137 
  
 
C 20 114.4 12.15 2.717 90 127 
  
 
Total 60 118.38 10.706 1.382 90 147 
  
SBP10 A 20 114.15 8.887 1.987 100 139 3.561 0.035 
 
B 20 117.35 11.061 2.473 100 138 
  
 
C 20 109.2 9.099 2.035 92 120 
  
 
Total 60 113.57 10.145 1.31 92 139 
  
SBP15 A 20 109.9 8.867 1.983 94 132 5.25 0.008 
 
B 20 118.2 12.344 2.76 92 140 
  
 
C 20 108.3 9.581 2.142 92 120 
  
 
Total 60 112.13 11.095 1.432 92 140 
  
SBP20 A 20 109.45 10.4 2.325 94 142 8.803 0.0001 
 
B 20 120.85 12.214 2.731 94 146 
  
 
C 20 107.3 10.204 2.282 90 126 
  
 
Total 60 112.53 12.343 1.594 90 146 
  
SBP25 A 20 109.1 12.49 2.793 94 146 8.398 0.001 
 
B 20 120 11.734 2.624 96 143 
  
 
C 20 105.95 9.73 2.176 90 126 
  
 
Total 60 111.68 12.725 1.643 90 146 
  
SBP30 A 20 111.25 13.932 3.115 90 146 7.308 0.001 
 
B 20 120 12.439 2.782 96 147 
  
 
C 20 105.95 8.029 1.795 90 120 
  
 
Total 60 112.4 12.932 1.669 90 147 
  
SBP35 A 20 113.3 12.704 2.841 94 146 7.183 0.002 
 
B 20 120.25 12.212 2.731 90 146 
  
 
C 20 106.7 8.542 1.91 90 120 
  
 
Total 60 113.42 12.435 1.605 90 146 
  
SBP40 A 20 115.75 9.797 2.191 100 142 9.361 0.0001 
  
 
Variables Group N Mean Std.  Deviation 
Std. 
Error Minimum Maximum F Sig. 
 
B 20 122.65 14.694 3.286 94 163 
  
 
C 20 107.55 7.373 1.649 89 119 
  
 
Total 60 115.32 12.518 1.616 89 163 
  
SBP45 A 20 116.3 9.274 2.074 100 146 9.244 0.0001 
 
B 20 122 12.057 2.696 102 158 
  
 
C 20 108.6 7.883 1.763 90 118 
  
 
Total 60 115.63 11.189 1.444 90 158 
  
SBP50 A 20 120.6 9.213 2.06 110 153 10.194 0.0001 
  B 20 122.3 9.437 2.11 108 147 
  
  C 20 110.3 8.615 1.926 89 120 
  
  Total 60 117.73 10.417 1.345 89 153 
  
SBP55 A 20 120.7 8.682 1.941 110 150 6.751 0.002 
 
B 20 121.75 9.657 2.159 104 145 
  
 
C 20 112.2 8.667 1.938 91 121 
  
 
Total 60 118.22 9.853 1.272 91 150 
  
SBP60 A 12 123.67 7.608 2.196 118 140 8.899 0.001 
 
B 17 124.24 9.384 2.276 106 147 
  
 
C 16 113.19 7.323 1.831 98 124 
  
 
Total 45 120.16 9.603 1.432 98 147 
  
SBP70 A 7 123.86 7.798 2.947 118 140 7.461 0.003 
 
B 10 126.1 5.547 1.754 120 140 
  
 
C 9 116 4.387 1.462 110 122 
  
 
Total 26 122 7.244 1.421 110 140 
  
 
 
This variable shows statistical significance after tenth minute of spinal 
anaesthesia . the p value is 0.001. 
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 DIASTOLIC BLOOD PRESSURE: 
DBPPREOP 
A 20 80.85 6.753 1.51 70 92 
0.59 0.558 B 20 78 7.567 1.692 64 93 C 20 79.5 10.185 2.277 65 110 
Total 60 79.45 8.241 1.064 64 110 
DBP2 
A 20 80.75 7.999 1.789 69 102 
1.365 0.264 B 20 76.3 7.651 1.711 60 87 C 20 77.8 10.139 2.267 65 113 
Total 60 78.28 8.72 1.126 60 113 
DBP5 
A 20 77.95 6.245 1.396 70 96 
2.015 0.143 B 20 76.25 6.512 1.456 66 91 C 20 72.45 12.437 2.781 56 112 
Total 60 75.55 9.022 1.165 56 112 
DBP10 
A 20 74.55 8.062 1.803 64 98 
4.34 0.018 B 20 76.85 6.201 1.387 69 94 C 20 70.1 7.704 1.723 58 88 
Total 60 73.83 7.773 1.003 58 98 
DBP15 
A 20 73.65 6.491 1.451 64 87 
8.398 0.001 B 20 76.75 4.179 0.934 69 86 C 20 68.6 7.83 1.751 54 87 
Total 60 73 7.1 0.917 54 87 
DBP20 
A 20 72.6 5.725 1.28 64 84 
9.3 0.0001 B 20 76.95 2.665 0.596 72 81 C 20 68.7 8.367 1.871 53 88 
Total 60 72.75 6.851 0.884 53 88 
DBP25 
A 20 70.5 6.091 1.362 57 81 
3.361 0.042 B 20 74.5 5.463 1.222 68 91 C 20 69.85 6.8 1.521 58 88 
Total 60 71.62 6.383 0.824 57 91 
DBP30 
A 20 71.3 5.048 1.129 64 84 
4.993 0.01 B 20 73.7 5.017 1.122 61 83 C 20 68.65 5.102 1.141 55 78 
Total 60 71.22 5.387 0.695 55 84 
DBP35 
A 20 72.9 5.647 1.263 64 86 
5.114 0.009 B 20 74.05 5.605 1.253 64 86 C 20 68.75 5.28 1.181 52 76 
Total 60 71.9 5.885 0.76 52 86 
DBP40 
A 20 73.25 6.086 1.361 60 84 
4.658 0.013 B 20 74.6 6.286 1.406 61 91 C 20 69.35 4.38 0.979 55 74 
Total 60 72.4 5.989 0.773 55 91 
  
 
DBP45 
A 20 75 3.92 0.877 68 82 
9.457 0.0001 B 20 75.65 5.412 1.21 64 86 C 20 68.65 7.088 1.585 48 75 
Total 60 73.1 6.38 0.824 48 86 
DBP50 
A 20 76.85 4.837 1.082 70 87 
5.77 0.005 B 20 75.75 5.26 1.176 65 85 C 20 70.9 7.29 1.63 51 83 
Total 60 74.5 6.353 0.82 51 87 
DBP55 
A 20 78.65 4.095 0.916 72 89 
7.044 0.002 B 20 76.9 6.078 1.359 61 86 C 20 72.65 5.234 1.17 60 81 
Total 60 76.07 5.707 0.737 60 89 
DBP60 
A 12 79.17 2.368 0.683 76 84 
7.572 0.002 B 17 76.06 5.662 1.373 69 86 C 16 72.19 4.996 1.249 60 80 
Total 45 75.51 5.417 0.808 60 86 
DBP70 
A 7 79.43 1.512 0.571 76 80 
8.081 0.002 B 10 78.5 5.759 1.821 67 86 C 9 72.33 2.55 0.85 70 78 
Total 26 76.62 4.981 0.977 67 86 
 
 
 
 
The diastolic blood pressure in all three groups were insignificant 
statistically during pre operative period. The diastolic blood pressure shows 
statistical significance in all three groups from tenth minute after spinal anaesthesia. 
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 OXYGEN SATURATION:  
 Variables Group N Mean Std. Deviation 
Std. 
Error Minimum Maximum F Sig. 
SPO2PREOP 
A 20 98.5 1.1 0.246 97 100 
1.502 0.231 
B 20 98.35 0.933 0.209 97 100 
C 20 98.9 1.071 0.24 97 100 
Total 60 98.58 1.046 0.135 97 100 
SPO22 
A 20 99.4 0.821 0.184 98 100 
0.429 0.654 
B 20 99.6 0.598 0.134 98 100 
C 20 99.5 0.607 0.136 98 100 
Total 60 99.5 0.676 0.087 98 100 
SPO25 
A 20 99.45 0.759 0.17 98 100 
2.053 0.138 
B 20 99.75 0.55 0.123 98 100 
C 20 99.8 0.41 0.092 99 100 
Total 60 99.67 0.601 0.078 98 100 
SPO210 
A 20 99.6 0.503 0.112 99 100 
0.784 0.461 
B 20 99.75 0.55 0.123 98 100 
C 20 99.8 0.523 0.117 98 100 
Total 60 99.72 0.524 0.068 98 100 
SPO215 
A 20 99.45 0.686 0.153 98 100 
0.754 0.475 
B 20 99.6 0.681 0.152 98 100 
C 20 99.7 0.571 0.128 98 100 
Total 60 99.58 0.645 0.083 98 100 
SPO220 
A 20 99.35 0.933 0.209 97 100 
1.712 0.19 
B 20 99.65 0.587 0.131 98 100 
C 20 99.75 0.55 0.123 98 100 
Total 60 99.58 0.72 0.093 97 100 
SPO225 
A 20 99.6 0.681 0.152 98 100 
0.146 0.865 
B 20 99.65 0.587 0.131 98 100 
C 20 99.7 0.47 0.105 99 100 
Total 60 99.65 0.577 0.075 98 100 
SPO230 
A 20 99.5 0.761 0.17 98 100 
1.221 0.303 
B 20 99.6 0.94 0.21 96 100 
C 20 99.85 0.366 0.082 99 100 
Total 60 99.65 0.732 0.095 96 100 
SPO235 
A 20 99.4 0.94 0.21 97 100 
2.577 0.085 
B 20 99.45 0.887 0.198 97 100 
C 20 99.9 0.308 0.069 99 100 
Total 60 99.58 0.787 0.102 97 100 
SPO240 
A 20 99.55 0.605 0.135 98 100 
1.177 0.316 
B 20 99.6 0.598 0.134 98 100 
  
 
 Variables Group N Mean Std. Deviation 
Std. 
Error Minimum Maximum F Sig. 
C 20 99.8 0.41 0.092 99 100 
Total 60 99.65 0.547 0.071 98 100 
SPO245 
A 20 99.9 0.308 0.069 99 100 
1.949 0.152 
B 20 99.7 0.47 0.105 99 100 
C 20 99.9 0.308 0.069 99 100 
Total 60 99.83 0.376 0.049 99 100 
SPO250 
A 20 99.65 0.587 0.131 98 100 
2.721 0.074 
B 20 99.45 0.826 0.185 97 100 
C 20 99.9 0.308 0.069 99 100 
Total 60 99.67 0.629 0.081 97 100 
SPO255 
A 20 99.75 0.444 0.099 99 100 
1.572 0.216 
B 20 99.85 0.366 0.082 99 100 
C 20 99.95 0.224 0.05 99 100 
Total 60 99.85 0.36 0.046 99 100 
SPO260 
A 12 99.75 0.452 0.131 99 100 
0.917 0.407 
B 17 99.88 0.332 0.081 99 100 
C 16 99.69 0.479 0.12 99 100 
Total 45 99.78 0.42 0.063 99 100 
SPO270 
A 7 99.57 0.535 0.202 99 100 
1.014 0.378 
B 10 99.4 0.699 0.221 98 100 
C 9 99.78 0.441 0.147 99 100 
Total 26 99.58 0.578 0.113 98 100 
 
 
As the table mentioned above shows that oxygen saturation has no statistical 
significance between the groups. 
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 TOTAL DURATION OF ANALGESIA: 
The total duration of analgesia were statistically significant in all three 
groups. In Group A the mean was 2.436 ± 0.2868 , in Group B it was 2.937 ± 
0.3352, in Group C it was 4.352± 0.6231. 
 
Descriptives Groups N Mean Std. Deviation 
Std. 
Error Minimum Maximum 
Total dur. Of 
analgesia 
A 20 2.436 0.2868 0.0641 2.1 3.1 
B 20 2.937 0.3352 0.0749 2.4 3.4 
C 20 4.352 0.6231 0.1393 3.4 5.2 
Total 60 3.242 0.9261 0.1196 2.1 5.2 
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 TOTAL DURATION OF MOTOR BLOCK: 
The total duration of motor block was found to be statistically significant 
between the groups. In Group A the mean was 3.072±0.3467 , in Group B it was 
3.401± 0.2172, in Group C mean was 3.412± 0.2328. 
 
Descriptives Groups N Mean Std. Deviation Std. Error Minimum Maximum 
dur.motor block 
A 20 3.072 0.3467 0.0775 2.5 3.5 
B 20 3.401 0.2172 0.0486 3.2 4.2 
C 20 3.412 0.2328 0.052 3.1 4.2 
Total 60 3.295 0.3108 0.0401 2.5 4.2 
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 VAS SCORE: 
 
Descriptives Groups N Mean Std. Deviation Std. Error Minimum Maximum 
VAS 
A 20 4.7 0.47 0.105 4 5 
B 20 4.9 1.071 0.24 4 9 
C 20 4.45 0.51 0.114 4 5 
Total 60 4.68 0.748 0.097 4 9 
 
 
 
 
The mean VAS score was not significant statistically as the p value is 0.163. 
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 SIDE EFFECTS: 
In Group A , out of 20 patients only one had complaints of mild chest pain . 
in Group B , out of 20 patients two patients had chest pain , one had cough 5 -6 
episodes ,two patients had complaints of nausea and 4 patients had vomiting during 
intraoperative and postoperative period. In Group C , out of 20 patients  6 patients 
had bradycardia , 4 patients had hypotension with bradycardia  and two patients had 
nausea. 
Group Side effect Frequency Percent 
A 
NIL 19 95 
chestpain 1 5 
Total 20 100 
B 
NIL 12 60 
chestpain 1 5 
cough,cp 1 5 
nausea 2 10 
Vomiting 4 20 
Total 20 100 
C 
NIL 8 40 
Brady 6 30 
Hypo 4 20 
Nausea 2 10 
Total 20 100 
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DISCUSSION 
Lower abdominal surgeries like hernioplasty , abdominal hysterectomy are 
commonly performed surgeries. Providing good analgesia with adequate  muscle 
relaxation during intra operative period and managing pain in the post operative 
period is a good practice of anaesthesia. As pain influences the morbidity and 
mortality of the patients, it’s important to ease pain due to surgery for better 
outcome of the patients. 
Commonly, lower abdominal surgeries are performed under spinal 
anaesthesia , as it is easy to perform , single shot technique when compared to 
epidural anaesthesia and general anaesthesia. But the main problem of spinal 
anaesthesia is that postoperative analgesia lasts only for considerable period.   
This study is conducted to analyse the effect of adding additives 50 µ of 
neostigmine and 50 µ of clonidine to 0.5% hyperbaric bupivacaine and evaluating 
the duration of postoperative analgesia with each drug and the intraoperative 
haemodynamic stability in patients undergoing lower abdominal surgeries. 
After preanaesthetic check-up and getting informed consent, 60 patients of 
ASA I and II of both sexes, between 20-60 yrs of age, who were scheduled to 
undergo lower abdominal surgeries of duration less than 90 mins wereincluded in 
the study. They were randomly allocated into 3 groups of 20 patients each. 
  
  
 
AGE: 
The mean age in all groups were comparable , Group A is 41.45 ±12.458, 
Group B is 43.4± 8.923, Group C is 39.15± 11.118. 
WEIGHT: 
The mean body weight of the patient in Group A is 60.1± 6.593  kg , Group 
B is 61.35 ± 9.213  and Group C is 61.25 ± 7.247 and is comparable in all three 
groups. 
SENSORY BLOCK: 
 ONSET TIME OF SENSORY BLOCK: 
In this study , the mean time for onset of sensory block was found to be 
176.2 ±6.948 sec in Group A, 96.9± 19.472 sec in Group B, 113.95± 14.666 in 
Group C. This shows that there is statistical difference between the three groups. 
Pan PM, Huang CT, Wei TT, Mok MS in 1998, conducted a study that  
compares the analgesic effect of intrathecally administered neostigmine and 
clonidine along with bupivacaine in spinal anaesthesia for patients undergoing 
caesarean section. They found that the onset of sensory block was rapid in 
neostigmine groups than clonidine groups. 
Yoganarasimha and co-worker in 2014 , compared intrathecal clonidine 
75µ versus intrathecal neostigmine 50µ as adjuvant drug for spinal anaesthesia 
0.5% hyperbaric bupivacaine 12.5 mg ;they also found that onset of sensory and 
  
 
motor block is faster in neostigmine when compared to clonidine and plain 
bupivacaine. 
 DURATION OF SENSORY BLOCK: 
In this study, the mean time for total duration of  sensory block was found to 
be 2.436 ± 00.6231.2868 in Group A, 2.937 ± 0.3352  in Group B, 4.352 ± 0.6231 
in Group C. This shows that there is statistical difference between the three groups. 
Elia et al, conducted a study including 1,445  patients , used intrathecal 
clonidine  as adjuvant to 0.5% hyperbaric  bupivacaine  and found that 15 – 150 µ 
prolonged  , the time to two segment regression (mean 14 to 75 min), delay in 
regression time to L2 that the duration of analgesia, the time to need for first rescue 
analgesic and motor block was extended without any relationship to dose.  
Andrieu et al in 2004 compared intrathecal morphine 4µ/kg  with and 
without clonidine 4µ/kg  in patients undergoing radical retropubic prostatectomy . 
adding clonidine to spinal morphine reduced intraoperative use of sufentanil and 
prolonged the total duration of analgesia. 
Strebel et al in 2004, studied about the effect of three different doses of 
clonidine (γ7.5,75 and 150 μg) when added to spinal 0.5% bupivacaine 18 mg in 80 
orthopaedics patients. The results showed that in group receiving intrathecal 
clonidine , the duration of sensory block was prolonged irrespective of the dose.  
  
  
 
MOTOR BLOCK: 
 ONSET TIME: 
The mean onset time for motor block in Group A is 166.2 ± 7.824, Group B 
is 96.2 ± 29.243, Group C is 102.75 ± 29.993 and were comparable between the 
groups. 
Kanazi et al in 2006 , compared clonidine 30 µ and dexmedetomidine 3µ 
added to 12 mg of 0.5% hyperbaric bupivacaine in spinal anaesthesia , versus 12 mg 
of hyperbaric bupivacaine alone in 60 transurethral resection of prostrate. Patient 
treated with alpha 2 agonist has rapid onset time of motor block and took longer 
time for sensory and motor regression .  
 DURATION OF MOTOR BLOCK: 
The total duration of motor block in Group A it was 3.072±0.3467 , in Group 
B it was 3.401± 0.2172, in Group C it was 3.412± 0.2328. 
Marrivirta et al , conducted a study in 60 ambulatory patients undergoing 
surgery , added 75µ of clonidine to 6 mg spinal hyperbaric bupivacaine with 6 mg 
bupivacaine alone. It showed that motor block was prolonged in patients who 
received clonidine.  
Tuijl et al, conducted a study in β010 in which the effect of 0, 15 and γ0 μg 
of clonidine along with 5 mg of 0.5% hyperbaric bupivacaine on the prolongation of 
motor block, analgesia and ability to void after knee arthroscopy. The study showed 
  
 
that clonidine increased the duration of motor block duration by 25 and 34 min 
respectively.  
Rochette et al, studied 75 patients who were given increasing doses of 
clonidine (0.β5, 0.5, 1 y β μg/kg) with plain spinal bupivacaine 0.5% (1 mg/kg) and 
concluded that clonidine 1 μg/kg produces improvement in spinal anaesthesia 
duration without significant side effects. 
Hood DD, Mallak KA, Eisenach JC, Tong C in 1996, studied the 
difference between spinal neostigmine and epidural clonidine. A total of 58 people 
received spinal injection of 5% dextrose in normal saline or neostigmine (50, 100, 
or 200 micrograms in D5NS), followed in 1 h by epidural saline or clonidine. The 
study showed that clonidine increased the duration of analgesia and motor block. 
HAEMODYNAMIC VARIABLES: 
Elia et al , studied 1,445  patients , using intrathecal clonidine  as adjuvant to 
bupivacaine  and found that there is increased incidence of arterial hypotension 
without the effect of dose and the risk of bradycardia. 
Marrivirta et al (2010), in 60 ambulatory patients undergoing surgery , 
added 75µ of clonidine to 6 mg spinal hyperbaric bupivacaine with 6 mg 
bupivacaine alone. This study showed that there is more vasopressor requirement 
and less post operative pain. 
Mercier et al in 1998 ,studied the effect of sufentanil 5 μg and clonidine γ0 
μg with  sufentanil 5 μg alone given in spinal anaesthesia to reduce pain in the first 
  
 
stage of labour, they stated that ‘clonidine potentiate labour analgesia and side 
effects such as hypotension, maternal pruritus and sedation were equal in both 
groups’. 
Chiari et al in 2011,conducted a study by using  clonidine alone in spinal 
anaesthesia for relieving pain during labour; in 36 parturients with cervical dilation 
< 6 cm; they compared 50, 100, and β00 μg intrathecal clonidine and found that 
labour pain was significantly reduced in all patients, analgesia duration was 
significantly longer with β00 μg (median 14γ; range of means75-210 min), with 
100 μg (median 118; range of means 60-180 min) and using 50 μg (median 45; 
range of means 25-150 min).Hypotension was associated with β00 μg and the need 
of intravenous ephedrine more often than in the other group. 
Rochette et al, studied 75 patients which were injected with increasing doses 
of clonidine  with plain spinal bupivacaine 0.5% (1 mg/kg) and concluded that  
hypotension and bradycardia were seen in 54% and 30% of patients respectively. 
Hood DD, Mallak KA, Eisenach JC, Tong C in 1996, studied the effects 
of  spinal neostigmine and epidural clonidine in human volunteers. The study 
results were ‘combination of neostigmine and clonidine resulted in an additive 
enhancement for analgesia, with  no enhancement of each drug's side effects, and 
also decreases clonidine-induced hypotension. Neostigmine injected into subjects in 
the lateral position diminished clonidine-induced reductions in blood pressure and 
plasma norepinephrine’. 
  
  
 
COMPLICATIONS: 
In Group A, the study showed that out of 20 patients only one had  
complaints of mild chest pain, in Group B , out of 20 patients only two patients had 
chest pain , one had cough 5 -6 episodes in itraoperative period ,two patients had 
complaints of nausea and 4 patients had vomiting during intraoperative and 
postoperative period and in Group C , out of 20 patients  6 patients had bradycardia, 
4 patients had hypotension with bradycardia  and two patients had nausea. 
Pan PM, Huang CT, Wei TT, Mok MS in 1998, conducted a study that 
states ‘comparison of  the analgesic effect of intrathecally administered neostigmine 
and clonidine along with bupivacaine in spinal anaesthesia for patients undergoing 
caesarean section’. 80 patients  who were posted for lower segment cesarean section 
using spinal anesthesia were divided into four groups: bupivacaine group - received 
10 mg of  bupivacaine alone; bupivacaine + neostigmine group - received 10 mg of 
bupivacaine + 50µ of neostigmine; bupivacaine + clonidine group  received - 10 mg 
of bupivacaine + 150µ of clonidine; bupivacaine + both received - 10 mg of 
bupivacaine + 50µ of neostigmine + 150µ of clonidine. This study found that the 
side effects such as nausea and vomiting and dizziness were significantly high in 
bupivacaine + both group’. 
  
  
 
SUMMARY 
This study was done to compare the use of neostigmine 50µ , clonidine 50µ 
along with 0.5% hyperbaric bupivacaine in spinal anaesthesia in patients 
undergoing lower abdominal surgeries in providing postoperative analgesia with 
stable haemodynamic status. 
A total of 60 patients were randomly allocated into three groups, 20 patients 
in each group. Group A received 2.5 ml of 0.5% hyperbaric bupivacaine, Group B 
received 50µ of neostigmine with 2.5 ml of 0.5% hyperbaric bupivacaine, Group C 
received 50µ of clonidine with 2.5 ml of 0.5% hyperbaric bupivacaine. Various 
haemodynamic parameters complications if any were recorded at second minute 
after spinal and every 5 minutes till the end of surgery. 
The observations were noted as follows 
Sensory block mean onset time for Group A is 176.2 ± 6.948, Group B is 
96.9 ± 19.472 and Group C is 113.95 ± 14.666. 
Motor block mean onset time is Group A is 166.2 ± 7.824, Group B is 96.2 ± 
29.243, Group C is 102.75 ± 29.993 seconds. 
Duration of surgical anaesthesia in Group A is 176.2 ± 6.948, Group B is 
96.9 ± 19.472 and Group C is 113.95 ± 14.666. 
Haemodynamic changes were significant between three groups. 
No significant changes were observed with  VAS score. 
Complications were seen in Group B nausea, vomiting, cough and chest pain 
and in Group C bradycardia and hypotension were seen.  
  
 
 
 
LIMITATIONS OF THE STUDY 
 
The selected sample size is small. 
Patients belong to ASAI/II only. 
  
  
 
 
CONCLUSION 
 
The observations of this study regarding the sensory and motor block onset 
time, duration of sensory and motor block, postoperative analgesia  show that spinal 
neostigmine has faster onset in both sensory and motor blockade, but spinal 
clonidine has longer duration of sensory and motor blockade, and has good post 
operative analgesia. 
The findings suggest that the use of clonidine 50µ along with 2.5 ml of 0.5% 
hyperbaric bupivacaine in lower abdominal surgeries has an added advantage in 
comparison with hyperbaric bupivacaine, as it provides longer duration of sensory 
and motor blockade, faster onset time of sensory block and good post operative 
analgesia, promotes early ambulation, shorter duration of hospital stay and thus 
reducing postoperative morbidity. Also it avoids multidrug exposure and its side 
effects. 
This study concluded that spinal clonidine 50µ along with 0.5% hyperbaric 
bupicaine is better than 0.5% hyperbaric bupivacaine alone as a effective adjuvant , 
providing good postoperative analgesia. 
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PROFORMA 
 
Name :                               Age  /sex:                             IP no :                          
Date of surgery : 
 
 Diagnosis :                                                                Surgery : 
 Weight :                                                     PR:                                   BP:    
 CVS:                                                          RS: 
 ABDOMEN:CNS: 
 Mallampati classification class:                 ASA PS class : 
 Investigations : 
 CBC:                                              ECG:  
 Platelets                                         CXR: 
 RFT:                                               ELECTROLYTES: 
 Urine routine:                              OTHERS:                              
 Premedication : 
 Preloading: 
 Spinal anaesthesia : 
 Drugs given : 
 Time of onset of analgesia: 
 Cephalad spread of analgesia: 
 Time taken for onset of motor blockade: 
 Quality of motor blockade: 
  
 
 Intraoperative haemodynamics: 
 
TIME  PR SPO2 NIBP 
2nd min    
5th min    
10th min    
15th min    
20th min    
25th min    
30th min    
35th min    
40th min    
45th min    
50th min    
55th min    
60th min    
65th min    
70th min    
75th min    
80th min    
85th min    
90th min    
 
 
 Sedation: 
 Total duration of analgesia: 
 Time of first rescue analgesia given: 
 Duration of motor block: 
 Other side effects: 
 
  
 
 
ஆரா்்சி தகவ் தா் 
 
செ்க்ப்ு அரு சபாு மு்ுவமனையி் மய்கவிய் 
ுனையில ஆரா்்ெி நனைசப்ு வுகி்ைு. 
நீ்கு் இ்த ஆரா்்ெியி் ப்கக்க நா்க் 
விு்பிகிகைா். இதைா் உ்கு்ு எ்த பாதி்ு் 
ஏ்பைாு எ்பனத சதிவி்ு் சகா்கிகைா். 
ுிுகனை அ்லு கு்ுகனை சவைியிு்கபாு 
அ்லு ஆரா்்ெியி்கபாு உ்கைு சபயனரகயா 
அ்லு அனையாை்கனைகயா சவைியிைமா்கைா் 
எ்பனது் சதிவி்ு் சகா்கிகைா். 
இ்த ஆரா்்ெியி் ப்கக்பு த்குனைய விு்ப்தி் 
கபி்தா் இு்கிைு. கமு் நீ்க் எ்த கநரு் இ்த 
ஆரா்்ெியிலிு்ு பி்வா்கலா் எ்பனது் 
சதிவி்ு் சகா்கிகைா். 
இ்த ெிை்ு பிகொதனைகைி் ுிுகனை ஆரா்்ெியி் 
ுிவி்கபாு த்கு்ு அைிவி்கபா் எ்பனது் 
சதிவி்ு் சகா்கிகைா். 
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130 124 116 112 94 108 100 114 112 120 120 124 117 118 118 
110 108 106 104 104 106 102 98 100 112 110 118 114 120 120 
126 124 120 106 108 102 98 106 112 118 124 126 130 128 128 
128 120 116 110 108 106 94 90 96 110 112 120 120 
130 122 116 118 110 112 110 114 116 108 110 112 118 120 120 
112 116 114 112 114 100 96 90 98 100 100 110 110 120 
126 124 118 112 110 106 104 108 112 117 114 119 124 120 
116 112 124 116 111 94 96 92 94 100 108 116 114 118 120 
120 118 116 114 100 98 94 97 106 110 112 110 117 121 
124 116 114 110 94 116 124 127 126 121 124 128 130 138 
126 118 104 100 106 110 118 124 125 123 119 124 120 
120 122 118 110 112 114 116 124 121 125 120 123 116 120 
 
 
 
DBPPR
EOP 
DB
P2 
DB
P5 
DBP
10 
DBP
15 
DBP
20 
DBP
25 
DBP
30 
DBP
35 
DBP
40 
DBP
45 
DBP
50 
DBP
55 
DBP
60 
DBP
70 
70 72 74 72 68 66 58 64 70 74 74 80 80 
84 82 79 70 70 70 68 70 64 70 72 74 80 
80 80 78 70 70 70 68 64 70 68 72 78 80 
70 72 70 73 68 68 72 74 70 70 76 70 80 
80 79 74 73 68 68 70 72 72 76 74 80 80 
74 69 82 64 64 64 57 65 70 64 69 70 76 
73 74 72 68 73 73 73 73 70 60 76 78 80 80 80 
88 82 76 74 72 72 76 70 76 78 72 70 74 76 76 
84 82 96 98 82 82 81 74 76 84 82 87 81 79 80 
80 76 74 74 70 70 64 72 76 72 74 76 78 80 80 
90 84 76 78 66 66 70 65 68 70 76 74 72 76 80 
  
 
92 102 90 89 84 84 79 84 86 79 74 80 80 
84 80 76 74 70 70 76 79 80 84 80 81 79 78 80 
70 74 76 72 78 68 66 67 70 71 70 80 80 80 
84 83 82 80 74 74 69 72 74 75 79 72 74 76 
82 96 74 72 76 73 71 68 64 71 77 78 80 84 80 
78 74 74 69 71 80 74 73 78 81 82 84 89 80 
90 86 84 83 87 80 70 72 75 73 76 80 84 81 
84 82 76 64 80 78 74 76 81 75 77 73 72 
80 86 76 74 82 76 74 72 68 70 68 72 74 80 
 
 
 
SPO2P
REOP 
SP
O22 
SP
O25 
SPO
2 10 
SPO
2 15 
SPO
2 20 
SPO
225 
SPO
230 
SPO
235 
SPO
240 
SPO
245 
SPO
250 
SPO
255 
SPO
260 
SPO
270 
98 100 98 99 99 100 100 100 99 99 100 99 99 
99 100 99 99 98 100 100 98 99 100 100 99 99 
97 99 98 100 98 97 100 100 100 99 99 99 99 
98 100 100 99 99 100 99 100 100 100 100 98 99 
100 100 100 100 100 99 98 100 99 99 100 100 100 
100 100 100 100 100 100 100 100 100 99 100 100 100 
97 100 98 99 99 100 100 98 99 100 100 100 100 100 100 
99 100 100 100 99 100 100 100 100 100 100 100 100 100 100 
97 98 99 99 100 99 99 99 97 98 99 99 99 99 99 
99 98 100 100 100 99 99 98 97 99 100 100 100 99 99 
97 99 100 100 99 98 100 99 100 100 100 100 100 100 100 
99 98 100 100 100 100 100 100 99 100 100 100 100 
100 100 99 99 100 100 100 100 100 100 100 100 100 99 99 
97 100 99 99 100 98 100 99 99 99 100 100 100 100 
98 99 100 100 100 99 98 99 100 100 100 100 100 100 
99 100 100 100 99 100 100 100 100 100 100 99 100 100 100 
98 99 100 100 100 98 99 100 100 99 100 100 100 100 
99 98 100 100 100 100 100 100 100 100 100 100 100 100 
100 100 99 99 100 100 100 100 100 100 100 100 100 
 
ONSET SPREAD MOTORBLOCK Totaldur.anal dur.motorblock sideeffect VAS 
164 8 156 2.4 3.3 5 
180 6 172 2.3 3.0 chestpain 4 
  
 
184 6 178 2.5 3.1 5 
179 6 170 2.6 3.3 4 
168 6 150 2.4 3.1 5 
186 8 174 2.1 3.4 5 
182 6 172 2.4 3.2 5 
179 6 176 3.0 3.5 4 
174 6 167 2.3 2.6 5 
182 4 172 3.1 3.5 5 
164 6 160 2.3 3.2 5 
180 4 164 2.5 3.4 4 
176 6 159 2.3 2.6 5 
168 6 154 2.5 3.4 5 
170 4 162 2.2 2.6 5 
174 6 168 2.5 3.2 5 
186 4 172 2.3 3.4 4 
176 6 159 2.3 2.6 5 
170 4 167 2.2 2.5 4 
 
  
  
 
GROUP – B 
 
S.
N
o 
Nam
e 
A
g
e 
S
e
x 
W
T 
dur.
sur
g 
PRP
REO
P 
P
R
2 
P
R
5 
P
R
10 
P
R
15 
P
R
20 
P
R
25 
P
R
30 
P
R
35 
P
R
40 
P
R
45 
P
R
50 
P
R
55 
P
R
60 
P
R
70 
1 
Vina
yaga
m 
3
4 M 
7
0 55 68 
7
8 
8
4 88 94 89 91 85 86 82 87 89 92 90 
2 Durai 
6
2 M 
6
4 65 65 
7
4 
7
2 70 76 70 78 81 84 82 74 79 73 75 77 
3 
Elan
gova
n 
5
3 M 
6
1 55 80 
8
0 
1
0
1 98 60 57 58 60 61 64 68 72 74 80 
4 
Krish
nan 
4
6 M 
4
0 60 89 
9
7 
9
6 91 87 81 78 83 87 85 80 77 80 86 86 
5 
Aru
muga
m 
6
0 M 
6
5 110 78 
9
1 
8
2 80 78 72 71 77 74 75 71 74 72 80 75 
6 
Palan
i 
4
2 M 
6
0 90 100 
8
7 
7
4 79 73 80 75 70 76 73 74 73 80 72 73 
7 
Sadiq
basha 
3
9 M 
6
8 55 124 
1
2
4 
1
1
9 
11
1 
11
0 99 96 84 87 90 89 87 85 
8 
Ram
adoss 
2
5 M 
5
8 80 83 
7
8 
8
3 74 68 79 82 81 79 86 84 87 81 81 82 
9 
Peria
samy 
4
6 M 
6
5 70 74 
9
6 
8
4 83 80 79 79 75 77 74 72 77 83 76 75 
10 
Siraj
begu
m 
3
2 F 
7
6 60 98 
9
4 
9
0 94 96 92 90 85 82 87 84 81 85 81 
11 
thebo
ral 
4
0 F 
6
2 85 90 
1
0
1 
8
0 80 86 79 86 72 74 85 91 89 94 88 85 
12 
Shant
hy 
4
0 F 
5
9 90 92 
9
0 
9
4 96 94 94 84 86 85 81 84 83 86 82 88 
13 
Vasu
ki 
4
5 F 
6
8 60 87 
9
2 
8
0 80 84 82 85 90 86 83 84 86 79 81 80 
14 
Kavit
ha 
3
7 F 
5
4 80 78 
7
6 
9
0 98 70 74 94 92 76 74 86 87 90 82 87 
15 
Daul
ath 
4
0 F 
4
9 55 60 
9
8 
9
4 90 
10
0 96 
10
0 92 96 90 86 84 87 85 
16 Selvi 
4
0 F 
5
9 45 75 
8
8 
8
4 85 87 90 88 84 85 86 80 80 80 
17 
Jayan
thy 
4
3 F 
6
7 65 68 
7
6 
7
2 75 73 72 72 71 68 67 76 72 74 78 
18 
Mali
ga 
5
4 F 
4
5 50 82 
9
6 
9
4 87 81 82 82 85 87 76 74 81 80 
19 
Jayak
umar
i 
4
5 F 
6
1 30 87 
8
9 
9
6 91 87 88 83 79 82 87 85 77 84 86 
20 Mega 4 F 7 65 92 1 1 96 94 94 91 93 86 84 81 79 82 80 
  
 
la 5 6 0
1 
0
7 
 
 
 
SBPPRE
OP 
SB
P2 
SB
P5 
SBP
10 
SBP
15 
SBP
20 
SBP
25 
SBP
30 
SBP
35 
SBP
40 
SBP
45 
SBP
50 
SBP
55 
SBP
60 
SBP
70 
120 122 118 110 112 114 116 124 121 125 120 123 116 120 
117 124 120 126 125 120 124 121 120 123 127 125 124 120 
108 104 102 100 96 110 112 108 115 124 127 121 122 126 125 
135 135 126 110 112 135 126 124 112 104 107 112 116 120 
140 143 135 125 137 134 135 147 146 163 158 147 145 147 140 
148 131 136 100 107 128 117 111 112 108 108 111 116 119 122 
154 142 134 138 140 146 143 143 141 146 133 140 137 137 128 
118 115 123 121 121 123 130 134 133 137 123 118 122 
138 135 124 112 117 122 125 117 125 128 130 127 124 127 123 
122 124 126 120 124 125 123 127 120 121 124 126 123 120 127 
130 126 124 120 117 100 96 107 111 117 118 124 127 134 
126 118 120 120 116 118 112 117 120 122 120 124 121 126 125 
126 120 118 118 120 116 111 118 124 120 125 127 124 127 123 
110 117 108 106 105 104 104 107 112 115 117 115 110 116 120 
140 148 137 135 136 131 128 127 129 124 126 127 132 130 128 
124 122 120 124 126 120 125 121 120 123 127 119 124 120 
116 126 124 125 120 124 121 119 124 120 123 126 120 
125 126 130 127 120 124 126 120 121 126 106 112 104 116 
130 122 120 110 122 126 124 128 124 128 124 120 120 
110 106 102 100 92 94 98 96 90 94 102 108 104 106 
110 108 112 110 111 117 120 108 106 110 115 117 120 121 
 
 
 
DBPPR
EOP 
DB
P2 
DB
P5 
DBP
10 
DBP
15 
DBP
20 
DBP
25 
DBP
30 
DBP
35 
DBP
40 
DBP
45 
DBP
50 
DBP
55 
DBP
60 
DBP
70 
80 86 76 74 82 76 74 72 68 70 68 72 74 80 
74 72 74 80 80 78 70 74 70 71 74 73 76 70 
74 82 78 80 80 76 71 76 73 75 74 73 74 70 76 
78 79 91 94 81 80 91 61 65 61 69 65 61 70 
90 82 76 80 76 77 80 83 86 91 84 85 83 83 80 
83 62 75 80 76 76 72 71 67 68 68 71 69 69 67 
80 86 79 80 76 81 78 74 77 75 70 81 86 80 86 
74 78 71 70 80 80 76 78 81 80 77 80 78 
93 82 90 76 74 76 72 70 77 80 81 85 83 80 81 
  
 
81 87 74 76 80 77 74 76 73 76 73 73 74 75 79 
84 72 79 78 78 72 69 76 77 75 86 84 81 83 
70 70 68 70 74 76 72 70 76 78 80 79 82 80 81 
86 84 82 82 80 80 74 72 79 82 78 74 82 86 84 
64 68 72 70 69 76 71 77 75 70 78 75 73 80 80 
76 82 74 71 76 75 75 81 69 74 76 73 75 72 71 
84 82 84 85 86 78 84 80 81 79 81 77 83 80 
69 72 74 76 76 75 75 74 72 71 74 75 80 
74 72 71 75 78 80 70 69 76 72 75 77 73 73 
70 74 75 69 70 72 75 71 73 75 77 72 80 
72 60 66 70 75 80 68 72 70 69 64 70 70 72 
84 80 72 75 70 74 73 69 64 70 74 73 75 70 
 
 
 
SPO2P
REOP 
SP
O22 
SP
O25 
SPO
210 
SPO
215 
SPO
220 
SPO
225 
SPO
230 
SPO
235 
SPO
240 
SPO
245 
SPO
250 
SPO
255 
SPO
260 
SPO
270 
99 100 100 100 99 100 100 100 100 100 100 100 100 100 
98 100 99 100 100 100 98 99 99 100 100 100 100 100 
99 99 100 100 100 99 100 100 98 99 99 99 100 100 99 
97 100 100 99 98 100 99 100 100 100 100 100 100 100 
99 99 99 100 100 100 100 100 100 99 100 100 100 100 99 
99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
97 100 100 100 100 99 99 100 100 99 99 100 100 100 100 
98 99 100 100 100 98 99 100 100 99 99 98 99 
99 100 100 98 99 100 100 100 99 99 100 100 100 100 98 
97 99 100 100 100 100 100 99 98 100 100 99 100 100 100 
99 100 100 99 100 100 100 100 100 100 100 99 100 100 
98 100 100 100 98 100 100 96 97 99 100 100 100 100 100 
99 100 100 100 100 100 99 99 99 100 99 99 99 99 99 
97 98 100 100 99 99 100 100 100 100 100 100 100 100 100 
99 100 100 100 99 100 100 100 99 98 99 97 99 99 99 
99 100 100 99 100 100 100 100 100 100 100 100 100 100 
99 100 100 100 100 100 100 99 100 100 100 99 100 
97 99 98 100 100 100 100 100 100 100 100 100 100 100 
99 100 99 100 99 99 100 100 100 100 99 99 100 
100 99 100 100 100 99 100 100 100 100 100 100 100 100 
98 100 100 100 100 100 99 100 100 100 100 100 100 100 
 
         
 
  
 
ONSET SPREAD MOTORBLOCK Totaldur.anal dur.motorblock sideeffect VAS 
182 6 172 3.0 3.0 5 
74 8 67 3.2 3.5 cough,cp 5 
96 6 124 2.5 3.3 4 
140 6 180 2.4 3.2 vomit 4 
90 8 60 3.1 3.5 vomit 5 
100 8 60 3.0 4.2 5 
68 8 90 2.4 3.2 5 
80 7 128 3.2 3.4 vomit 5 
120 6 79 3.2 3.6 5 
102 6 90 3.2 3.6 nausia 5 
116 4 125 3.4 3.5 5 
110 4 128 2.6 3.3 chestpain 5 
104 6 96 3.0 3.2 4 
80 6 82 3.2 3.4 5 
94 4 70 3.3 3.5 nausia 9 
106 6 94 2.4 3.4 5 
74 6 80 3.0 3.2 4 
120 4 110 3.1 3.4 vomit 4 
70 6 90 3.2 3.5 5 
110 4 95 3.2 3.5 4 
84 6 77 2.6 3.2 5 
 
 
GROUP – C 
 
S.
N
O. 
NAM
E 
A
G
E 
S
E
X 
W
T 
DUR.OF.
SURGER
Y 
PR
EO
P 
P
R
2 
P
R
5 
P
R
10 
P
R
15 
P
R
20 
P
R
25 
P
R
30 
P
R
35 
P
R
40 
P
R
45 
P
R
50 
P
R
55 
PR 
60 
PR 
65 
1 
Aruna
chala
m 44 1 
6
4 75 76 
7
4 
6
7 61 68 54 69 68 69 70 73 63 62 65 
2 
Arum
ugam 25 1 
5
7 80 88 
8
9 
8
4 79 77 74 78 76 79 72 70 65 63 64 
3 
Partha
sarath
y 49 1 
7
8 55 84 
7
1 
7
4 67 61 54 69 68 69 70 63 65 58 
4 Karthi 20 1 
5
4 80 84 
9
5 
9
6 75 74 60 64 62 66 68 70 75 80 78 
5 
Venka
tesan 21 1 
7
5 90 94 
8
0 
7
3 64 57 64 68 67 66 68 67 65 62 71 75 
6 Kumar 30 1 
5
5 70 104 
1
0
7 
1
0
3 
10
2 92 90 86 83 85 89 85 80 85 79 73 
7 
Eluma
lai 56 1 
6
8 90 72 
7
7 
6
9 76 80 71 70 68 64 70 68 62 61 58 61 
  
 
8 
Rama
doss 25 1 
5
6 80 83 
7
8 
8
3 74 68 65 60 62 53 57 55 54 71 79 87 
9 
Manic
ham 52 1 
6
8 65 92 
8
6 
7
3 72 66 64 66 68 72 66 64 69 72 71 69 
10 
Mano
har 45 1 
6
2 60 87 
8
1 
7
0 74 72 71 68 72 72 76 73 75 72 75 75 
11 
Sivapr
akasa
m 57 1 
5
9 70 85 
7
7 
7
2 76 69 72 78 72 73 73 75 71 74 79 70 
12 
MD 
kaja 26 1 
6
4 45 90 
8
4 
7
3 73 70 75 77 70 74 77 75 74 74 
13 
Dinah
aran 46 1 
4
9 45 97 
9
4 
8
1 86 85 84 83 83 80 70 74 74 74 76 
14 
Santha
kumar 44 1 
5
8 60 81 
7
6 
7
4 64 63 60 59 54 78 79 72 70 73 75 
15 
Gandh
imathy 30 2 
6
2 70 84 
8
9 
7
2 74 76 70 68 70 74 72 71 71 70 72 75 
16 
Pushp
a 49 2 
5
6 60 92 
8
4 
7
0 71 69 64 67 68 68 72 69 63 72 72 
17 
Jayach
andra 44 2 
6
7 80 79 
7
9 
7
4 77 69 67 72 70 71 68 72 75 73 71 70 
18 Latha 47 2 
5
7 60 68 
6
4 
6
3 59 74 72 70 71 69 64 65 73 72 75 
19 
Chand
ra 40 2 
6
1 45 72 
7
7 
7
0 72 78 76 70 68 64 66 64 67 65 
20 
Sudha
devi 33 2 
5
5 50 79 
7
6 
7
4 67 63 69 64 69 68 73 70 73 72 
 
 
 
 
SBPPRE
OP 
SB
P2 
SB
P5 
SBP
10 
SBP
15 
SBP
20 
SBP
25 
SBP
30 
SBP
35 
SBP
40 
SBP
45 
SBP
50 
SBP
55 
SBP
60 
SBP
70 
106 93 98 97 92 93 97 90 90 91 90 89 91 100 
130 124 121 118 117 114 110 112 117 111 98 94 100 98 
107 100 93 98 97 92 93 97 98 100 106 117 120 
133 120 116 110 110 105 106 108 105 107 106 113 110 113 
139 140 127 120 114 117 116 114 110 111 115 118 118 124 122 
134 138 126 120 120 126 126 111 116 115 108 114 119 117 121 
120 127 126 110 116 113 104 115 113 108 105 106 98 106 111 
138 126 121 110 103 111 109 105 107 110 109 111 111 116 112 
110 107 106 100 93 97 98 93 91 89 94 96 100 107 110 
124 121 124 116 115 115 110 109 107 110 106 110 112 109 120 
130 123 120 115 109 109 104 109 108 113 117 112 110 114 116 
116 114 117 112 111 113 109 105 107 110 116 120 120 
127 120 120 118 112 115 117 98 100 106 109 110 110 120 
127 120 117 114 118 110 121 120 120 119 117 119 115 117 
116 107 90 92 97 90 90 98 100 112 116 115 117 119 116 
  
 
124 127 120 110 117 109 106 112 117 110 113 112 115 116 
118 107 105 98 94 90 90 96 98 110 118 120 121 120 116 
134 130 127 120 114 114 107 108 108 110 116 115 117 115 
110 98 94 96 99 100 108 109 106 109 109 110 120 
131 127 120 110 118 113 98 110 116 100 104 105 120 
 
  
  
 
 
 
DBPPR
EOP 
DB
P2 
DB
P5 
DBP
10 
DBP
15 
DBP
20 
DBP
25 
DBP
30 
DBP
35 
DBP
40 
DBP
45 
DBP
50 
DBP
55 
DBP
60 
DBP
70 
65 65 56 58 54 55 61 55 52 55 54 51 60 60 
70 78 70 70 68 64 60 63 68 64 60 64 67 70 
70 65 56 58 64 55 61 65 71 72 48 60 64 
75 73 58 59 55 53 58 62 68 69 64 70 71 69 
89 83 74 75 72 72 71 69 67 67 72 73 75 71 73 
110 113 112 88 87 88 88 74 73 73 72 83 81 76 78 
84 87 86 82 80 76 75 67 64 73 74 75 70 68 71 
93 77 72 67 67 69 71 70 68 67 72 62 68 72 70 
72 70 68 64 59 64 72 73 68 71 69 70 72 74 74 
76 73 70 64 68 60 63 67 65 69 72 71 72 70 70 
85 80 79 74 71 70 73 69 76 74 72 70 73 73 71 
76 78 70 69 69 73 75 71 70 72 70 76 78 
87 83 70 78 74 70 73 72 75 71 74 76 78 80 
76 74 73 69 68 72 74 70 72 70 74 70 74 78 
82 79 75 73 69 68 68 70 72 74 73 75 72 70 71 
75 75 72 70 74 75 71 65 63 65 68 70 72 70 
84 83 84 74 72 75 71 70 68 69 68 70 72 74 73 
76 73 78 75 73 72 70 75 73 71 72 76 78 80 
72 70 64 68 60 74 72 78 73 72 70 78 78 
73 77 62 67 68 69 70 68 69 69 75 78 78 
 
  
  
 
 
 
SPO2P
REOP 
SP
O22 
SP
O25 
SPO
210 
SPO
215 
SPO
220 
SPO
225 
SPO
230 
SPO
235 
SPO
240 
SPO
245 
SPO
250 
SPO
255 
SPO
260 
SPO
270 
99 100 99 98 99 100 99 100 100 100 100 100 100 99 
99 99 100 99 100 99 100 100 100 99 99 99 99 99 
99 99 100 100 100 100 99 100 100 100 99 100 100 
99 100 100 100 100 100 100 100 100 100 100 99 100 100 
100 100 100 100 100 100 99 100 100 100 100 100 100 100 100 
97 99 99 100 98 98 99 99 100 100 100 100 100 100 100 
98 98 99 100 99 99 100 100 99 99 100 100 100 100 100 
99 99 100 100 99 100 100 99 100 100 100 100 100 100 100 
98 99 100 100 100 100 100 100 100 99 100 100 100 99 100 
99 100 100 100 100 100 99 100 100 99 100 100 100 100 100 
97 99 100 100 99 100 100 100 99 100 100 100 100 100 99 
98 99 99 99 100 100 100 100 100 100 100 100 100 
99 100 100 100 100 100 99 99 100 100 100 100 100 100 
97 99 100 100 100 99 100 100 100 100 100 100 100 99 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 
100 100 100 100 100 100 100 100 100 100 100 100 100 99 99 
100 100 100 100 100 100 100 100 100 100 100 100 100 100 
100 100 100 100 100 100 100 100 100 100 100 100 100 
100 100 100 100 100 100 100 100 100 100 100 100 100 
 
 
 
 
 
 
ONSET SPREAD MOTORBLOCK Totaldur.anal dur.motorblock sideeffect VAS 
120 6 68 5.2 3.5 brad 5 
154 6 149 4.6 3.2 nausea 4 
120 6 60 5.3 3.5 brad 5 
110 6 84 4.2 3.4 hypo 5 
120 6 190 5.1 3.5 hypo 4 
100 6 90 4.4 3.1 
 
4 
80 6 65 5.1 3.4 brad 5 
120 6 110 4.2 3.6 brad 4 
113 8 95 4.3 3.4 hypo 4 
106 8 90 3.4 3.3 
 
5 
117 6 130 4.1 3.6 
 
4 
110 6 115 5.0 3.4 nausea 4 
130 6 124 4.2 3.3 
 
5 
110 8 100 3.4 3.2 brad 5 
98 6 90 3.6 3.5 
 
4 
100 6 110 4.1 3.5 
 
4 
117 7 95 3.4 3.2 hypo 5 
120 6 84 4.2 3.2 brad 4 
110 6 110 5.3 3.5 
 
4 
124 6 95 4.4 4.2 
 
5 
  
 
 
 
GLOSSARY: 
 IASP   International Association of the Study of Pain 
 CSF   Cerebrospinal fluid 
 PR   Pulse Rate 
 SBP  Systolic Blood Pressure 
 DBP  Diastolic Blood Pressure 
 NIBP  Non invasive Blood Pressure 
 CVS  Cardiovascular System 
 RS  Respiratory System 
 CNS  Central Nervous System 
 WT  Weight 
 ASA  American Society of Anaesthesiologist 
 VAS  Visual Analogue Scale 
 
 
